Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


ENZYME OR COENZYME CONTAINING

Subclass of:

424 - Drug, bio-affecting and body treating compositions

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
424940600 Hydrolases (3. ) (e.g., urease, lipase, asparaginase, muramidase, etc.) 881
424940500 Transferases (2. ), Lyase (4.), Isomerase (5.), Ligase (6.) 200
424940400 Oxidoreductases (1. ) (e.g., catalase, dehydrogenases, reductases, etc.) 170
424940300 Stabilized enzymes or enzymes complexed with nonenzyme (e.g., liposomes, etc.) 135
424940200 Multienzyme complexes or mixtures of enzymes 93
Entries
DocumentTitleDate
20090214505Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof - Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.08-27-2009
20090196861Biocompatible Latent Emulsifiers - A category of biocompatible dual-purpose emulsifiers for therapeutic and/or nutritional use is disclosed. The emulsifiers have at least two functions, which depend on pH and surrounding environment. In the anhydrous environment, they serve as nonionic solvents to dissolve the hydrophobic material, such as a hydrophobic drug or nutrient. When in the alkaline aqueous environment of the small intestine, they are transformed into a biocompatible ionic emulsifier. The emulsifiers can also be used to thin the surfactant/hydrophobe mixture in self-emulsifying bases and, thus, accelerate the emulsifying speed of the base without overloading the emulsifying capacity of the emulsion base.08-06-2009
20110195058CARDIOVASCULAR SUPPORT SUPPLEMENT AND COMPOSITIONS AND METHODS THEREOF - A cardiovascular support composition is provided comprising red yeast rice, Coenzyme-Q10, and phytosterols. A method for maintaining cardiovascular health is also provided comprising administering the composition comprising red yeast rice, Coenzyme-Q10, and phytosterols in a predefined dosage to an individual in need thereof.08-11-2011
20100158884Cascade - The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.06-24-2010
20100158883Human aminoacyl-tRNA synthetase polypeptides useful for the regulation of angiogenesis - A method of suppressing angiogenesis in a mammal (e.g., for treating tumors, tumor metastasis or a condition that would benefit from decreased angiogenesis) comprises the step of administering to the mammal an angiostatically effective amount of a pharmaceutical composition comprising an isolated antiangiogenic truncated tryptophanyl-tRNA synthetase (TrpRS) polypeptide or an isolated nucleic acid that comprises a polynucleotide sequence that encodes the truncated TrpRS polypeptide. The truncated TrpRS polypeptide comprises residues 71-471 of SEQ ID NO: 10, residues 48-471 of SEQ ID NO: 10, or a polypeptide of approximately 47 kD molecular weight produced by cleavage of the polypeptide of SEQ ID NO: 10 with polymorphonuclear leucocyte elastase.06-24-2010
20100119499STILBENE-BASED COMPOSITIONS AND METHODS OF USE THEREFOR - Disclosed are compositions, formulations and methods relating to one or more stilbene-based compounds for use in humans. In particular, compositions and formulations comprising an effective amount of the stilbene-based insulinogenic compound can improve athletic performance, lower blood glucose levels, and increase lean muscle mass when administered (e.g., orally) to a human.05-13-2010
20100119498DIETARY SUPPLEMENT FOR PROMOTING WELLNESS AND WEIGHT LOSS AND METHODS OF ADMINISTERING THE SAME - Disclosed herein are dietary supplements for promoting wellness and weight loss in a subject. In one aspect, the method includes administering to a subject whom wishes to lose weight a dietary supplement containing an extract product of 05-13-2010
20100074880POLYETHYLENE GLYCOL DERIVATIVE - The present invention includes a novel polyethylene glycol derivative; a drug carrier comprising the derivative; and a pharmaceutical composition comprising the drug carrier having a pharmacologically active substance included therein. Specifically disclosed are: a polyethylene glycol derivative represented by the general formula (I); a drug carrier comprising the derivative and 2-O-(2-diethylaminoethyl)carbamoyl-1,3-O-dioleoyl-glycerol; and a pharmaceutical composition comprising the drug carrier and a pharmacologically active substance (preferably double-stranded RNA, double-stranded DNA or an oligonucleic acid), wherein R represents a saturated or unsaturated aliphatic hydrocarbon group having 10 to 30 carbon atoms or a saturated or unsaturated fatty acid residue having 10 to 30 carbon atoms; and n represents an integer of 30 to 150.03-25-2010
20100074879SKIN AGENT FOR EXTERNAL USE AND COSMETIC AGENT INCLUDING UBIQUINONE DERIVATIVE OR SALT THEREOF AND METHOD USING THE SAME - A skin agent for external use and a cosmetic agent are provided, by transdermal administration of which expected actions and effects of ubiquinone derivatives, salts thereof, ubiquinones and ubiquinols are effectively obtained.03-25-2010
20120244135Use Of Anogeissus Extract For Fibrillin Production In Skin - Use of at least one extract from the 09-27-2012
20120244134PROCESS FOR PREPARING AQUEOUS DISPERSIONS CONTAINING HIGH CONCENTRATION OF NANO/SUBMICRON, HYDROPHOBIC, FUNCTIONAL COMPOUNDS - The present invention provides a process for preparing an aqueous dispersion containing a high concentration of nano/submicron, hydrophobic, functional compounds. The process is carried out by using a complex stabilizer having an HLB value of about 10 to about 17, comprising lecithin and at least one non-phospholipid selected from polysorbate, sucrose ester, and polyglycerol fatty acid ester; selecting a specific weight ratio of the hydrophobic functional compounds and the stabilizer; and using homogenization technique, media milling technique, and/or centrifugal technique. The aqueous dispersion containing a high concentration of nano/submicron, hydrophobic, functional compound produced by the process of the invention has stable dispersibility and improved bioavailability, and can be applied to the fields of foods and pharmaceuticals.09-27-2012
20130078227EMBEDDED CHIMERIC PEPTIDE NUCLEIC ACIDS AND USES THEREOF - The present invention relates to an ecPNA having the general structure:03-28-2013
20130078228VITAMIN-CONTAINING NUTRITION INFUSION FOR ADMINISTRATION THROUGH PERIPHERAL VEIN - A nutrition infusion is provided for administration through a peripheral vein that contains a vitamin B group and vitamin C stably and includes two solutions of a sugar solution and an amino acid solution. In the nutrition infusion for administration through a peripheral vein, the sugar solution contains vitamin B1, vitamin B12, and pantothenic acid and has a pH of 4.7 to 5.5, and the amino acid solution contains vitamin B2, folic acid, vitamin C, and biotin and has a pH of 7.0 to 7.5.03-28-2013
20120183522BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I:07-19-2012
20120183521EQUINE NUTRITIONAL SUPPLEMENT - A nutriceutical supplement for use in equines provides enhanced mitochondrial energizing activity and reduced inflammation and results in enhanced resistance to training injuries and diseases and enhances peak racing performance. The supplement is provided along with equine feed as a formulation including at least Coenzyme Q10, Carnitine, d-Ribose, Boswellia extract and Curcumin. These ingredients provide enhanced mitochondrial energizing activity and reduced stress, inflammation and injuries.07-19-2012
20130084272COMPOSITIONS, KITS AND METHODS FOR NUTRITIONAL SUPPLEMENTATION WITH TWELVE CARBON CHAIN FATTY ACIDS AND TWELVE CARBON CHAIN ACYLGLYCEROLS - The present invention relates to compositions, kits and methods for the administration of compositions and kits for supplementation with twelve carbon chain fatty acids or twelve carbon chain acylglycerols; and specifically for the supplementation with twelve carbon chain fatty acids such as lauric acid and twelve carbon chain acylglycerols such as monolaurin; and specifically for the co-supplementation with other vitamins, minerals and nutrients.04-04-2013
20090208473COMPOSITIONS AND METHODS TO MODULATE CELL MEMBRANE RESEALING - Disclosed herein are compositions and methods for repairing cell membranes. In addition, the invention relates to therapeutic compositions comprising nucleotides and/or polypeptides of the invention in combination with a pharmaceutically acceptable carrier, wherein the composition facilitates the repair of cell membranes. Moreover, the invention relates to the treatment and/or prevention of pathological conditions associated with cell membrane damage.08-20-2009
20120207731METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME - An object of the present invention is to provide a substance characterized by ability to reduce oxidized coenzyme Q10 and ability to stabilize reduced coenzyme Q10, which contains nutrients, has a favorable taste, and is excellent in general versatility, and a method for using the same. The present invention relates to a method for producing reduced coenzyme Q10 comprising reducing oxidized coenzyme Q10 with a particular amino acid. The present invention also relates to a method for stabilizing reduced coenzyme Q10 in the presence of a particular amino acid and a composition stabilized by the method.08-16-2012
20100098676SYNERGISTIC ANTI-INFLAMMATORY AND ANTIOXIDANT DIETARY SUPPLEMENT COMPOSITIONS - Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and antioxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.04-22-2010
20120263698Treatment of Neurodegenerative Disease - A method for reducing alpha-synuclein amyloid protein in a patient suffering from Parkinson's Disease comprising administering to the patient an effective amount of trans-resveratrol, a method for treating a neurodegenerative disease associated with amyloid proteins comprising administering to a patient in need thereof an effective amount of trans-resveratrol, and a method for treating Parkinson's Disease comprising administering to a patient in need thereof a pharmaceutically effective amount of carbidopa, levodopa, and trans-resveratrol are described. More particularly, the effect of trans-resveratrol on reducing the pharmaceutically effective dose of at least one of carbidopa and levodopa in the treatment of Parkinson's Disease is described. In addition, a method of improving cognition, speech and/or movement in a patient suffering from Parkinson's Disease comprising administering to the patient carbidopa, levodopa and trans-resveratrol is described.10-18-2012
20100111918METHODS OF ADMINISTERING TETRAHYDROBIOPTERIN, ASSOCIATED COMPOSITIONS, AND METHODS OF MEASURING - The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.05-06-2010
20090155235AGGREGATES WITH INCREASED DEFORMABILITY, COMPRISING AT LEAST THREE AMPHIPATS, FOR IMPROVED TRANSPORT THROUGH SEMI-PERMEABLE BARRIERS AND FOR THE NON-INVASIVE DRUG APPLICATION IN VIVO, ESPECIALLY THROUGH THE SKIN - The invention describes combinations of at least three amphipatic substances forming aggregate suspensions in a polar liquid. Judicious choice of system components, which differ at least 2-times to 10-times in solubility, ensures said aggregates to have extended, unusually adaptable surfaces. This is probably due to simultaneous action on said aggregates of at least two more soluble substances amongst said three system components, at least one of which is an active ingredient and preferably a drug; the third component alternatively, can take the role of a drug. The patent further deals with the use of said combinations in pharmaceutical preparations capable of transporting drugs into the body of warm blood creatures. This is made possible by the drug loading capability of said aggregates with the highly flexible and deformable coating, which renders the resulting drug carriers highly adaptable. The patent finally reveals suitable methods and favourable conditions for carrier manufacturing and application.06-18-2009
20130045193COMPOSITIONS AND METHODS FOR THE PREVENTION OF CARDIOVASCULAR DISEASE - The present invention relates to compositions comprising vitamins, minerals and other nutrients and methods for using these compositions for nutritional supplementation to prevent and/or alleviate a patient from the occurrence or negative effects of cardiovascular disease. Specifically, the invention relates to compositions and methods of administering compositions comprising natural CoQ02-21-2013
20130089533DISINFECTANT COMPOSITIONS WITH HYDROGEN PEROXIDE - Disinfectant compositions include 0.001 to 10% by weight of hydrogen peroxide or a hydrogen peroxide source based on the total weight of the composition; 0.001 to 20% by weight of at least one amphoteric surfactant based on the total weight of the composition; and 0.001 to 15% by weight of at least one alkali metal or alkaline earth metal salt of a cyclic or heterocyclic aromatic compound comprising at least one hydroxyl group, carboxylic group, or combination thereof based on the total weight of the composition. The disinfectant compositions are particularly effective at treating surfaces contaminated with resistant bacteria, such as 04-11-2013
20130052175OIL SUSPENSION-BASED MOLDED FOOD PRODUCTS - A molded food product is provided that has a high fat and protein content and a low carbohydrate content. The food product is suitable for human or animal consumption. The food product can serve as a snack or as a carrier for active ingredients such as vitamins, minerals, herbs and other food additives.02-28-2013
20080311099Pyridoxal-5-Phosphate and Related Compounds in Combination With Therapeutic Cardiovascular Compounds for Treating Angina - Methods for treating angina are described. A method for treating angina includes concurrently administering a compound with a therapeutic cardiovascular compound. A combination therapy employs suitable therapeutic cardiovascular compounds, such as a calcium channel blocker, a β-adrenergic blocker, nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, or a mixture thereof, in combination with a compound such as pyridoxal-5′phosphate, pyridoxic acid, pyridoxal, pyridoxamine, 3-acylated analogues of pyridoxal, 3-acylated analogues of pyridoxal-4,5-aminal, pyridoxine phosphonate analogues, a pharmaceutically acceptable acid addition salt thereof, or a mixture thereof. The invention also includes a novel composition comprising at least one compound and nitrates, partial fatty acid oxidation inhibitors, potassium channel activators, calcium channel blockers, β-adrenergic blockers, or a mixture thereof.12-18-2008
20090304662Methods for Identifying and Targeting Tumor Stem Cells Based on Nuclear Morphology - Described herein are methods for inhibiting tumor growth comprising targeting a tumor stem cell in the patient with an agent or treatment that chemically modifies a tumor stem cell-specific molecule, thereby preventing proliferation of tumor stem cells.12-10-2009
20130071370INHIBITORS OF MICRO-RNAS FOR USE FOR PREVENTING AND/OR ATTENUATING SKIN AGEING AND/OR FOR HYDRATING SKIN - Method of identifying and using compounds which inhibit the expression or activity of micro-RNAs for preventing and/or attenuating ageing, and/or for hydrating skin. An in vitro method for screening for candidate compounds for preventing and/or attenuating ageing of the skin, and/or for hydrating the skin, includes the following steps: 03-21-2013
20130071369Oral Formulations For Promoting Cellular Purification - An oral formulation includes a plurality of agents that promote cellular detoxification. Agents can be included that modulate expression of Nrf2-associated genes upon ingestion of the oral formulation by a subject, wherein the Nrf2-associated genes include at least one gene encoding intrinsic antioxidants, and at least one gene encoding cellular detoxifiers. In addition, at least one of the plurality of agents attenuates inflammation.03-21-2013
20110014172Recombinant Human CLN2 Protein and Methods of Its Production and Use - The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein.01-20-2011
20100003230tRNA SYNTHETASE FRAGMENTS - The present invention relates to compositions and methods for treating conditions associated with angiogenesis. In particular the present invention relates to multi-unit complexes of tRNA synthetase fragments and uses thereof; diverse multi-unit complexes including a tRNA synthetase fragment; compositions and methods for modulating angiogenesis; polynucleotides encoding tRNA synthetase fragments and uses thereof; antibodies and epitopes specific to tRNA synthetase fragments; variants of tRNA synthetase fragments and uses thereof; methods for treating angiogenesis; methods for screening for anti-angiogenic agents; methods of modulating angiogenesis; kits for modulating angiogenesis; and business methods for modulating angiogenesis. Preferably the tRNA synthetase fragments are tryptophanyl tRNA synthetase fragments, and more preferably human tryptophanyl tRNA synthetase fragments.01-07-2010
20090068163Transgenic expression cartridges for expressing nucleic acids in the flower tissue of plants - The invention relates to methods for the targeted transgenic expression of nucleic acid sequences in tissues of plants, and to transgenic expression cassettes and expression vectors comprising promoters with expression specificity for floral tissues. The invention further relates to organisms (preferably plants) transformed with these transgenic expression cassettes or expression vectors, to cultures, parts or propagation material derived from these organisms, and to their use for the production of foodstuffs, feedstuffs, seed, pharmaceuticals or fine chemicals.03-12-2009
20090238810OPHTHALMIC COMPOSITION - An ophthalmic composition is provided which is capable of enhancing a barrier function of a lipid layer that constitutes a tear film, for thereby restricting and curing corneal disorders such as dry eye. It is also an object of the invention to provide the ophthalmic composition with anti-inflammatory and antimicrobial effects for thereby advantageously preventing and easing corneal/conjunctival disorders such as keratoconjunctivitis. In the present invention, apolipoprotein A-1 is included, as an active ingredient, in the ophthalmic composition.09-24-2009
20090238809Application Methods to Rapidly Alter Disease and Injury States Using Molecular Transport of B6 - The present invention discloses methods of application employing B51B6 vitamins in molecular transport creams or gels to deliver B6 in a high dose to bring about therapeutic ways in human or mammal tissues to reverse a disease process or injury to bring about normal function of the affected tissues. Examples of disease changes to normal include, but are not limited to strokes, cellulitis, facial acne, precancerous lesions, nerve injury like paresthesia, periorbital hematoma, pentathol general anesthesia recovery, headaches, improved sight, hypothyroidism, dental pain, dental gingivitis, insect bites, delayed hypersensitivity states, phlebitis of veins and synergism of steroid activity.09-24-2009
20080267939SYNERGISTIC ANTI-HYPERTENSIVE PHYTO-NUTRACEUTICAL COMPOSITION - A Phyto-nutraceutical composition for the prevention and treatment of hypertensive disorders is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effect.10-30-2008
20110044963Method of Testing a Patient for Hypertension and Related Method of Treatment and Test Kit - A method of testing a patient for hypertension includes providing a urine specimen from the patient, performing a first test on the urine specimen to determine if volume expansion hypertension exists by measuring the level of marinobufagenin in the urine specimen, performing a second test on the urine specimen to determine if vasoconstrictive hypertension exists by measuring the level of angiotensinogen in the urine specimen, and performing the first and second tests on the urine specimen substantially simultaneously without either test having an adverse effect on the other test. The tests may employ a test strip having a first region for use in the first test and a second region for use in the second test with each region effecting a visible change if the condition for which the test is being formed is found to exist. A related method of treatment and a related test kit are also disclosed.02-24-2011
20090041738Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells - The present invention provides novel methods for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator, wherein the inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors.02-12-2009
20120114625SHELF-STABLE FERMENTED DAIRY PRODUCTS AND METHODS OF MAKING SAME - Shelf-stable fermented dairy products and methods of making the shelf-stable fermented dairy products are provided. The shelf-stable fermented dairy products can be shelf-stable with improved taste, viscosity and texture profiles. In a general embodiment, the present disclosure provides a shelf-stable fermented dairy product including a shelf-stable fermented dairy component, a stabilizer, and a puree composition. The shelf-stable fermented dairy component can be, for example, yogurt, sour cream, buttermilk or a combination thereof.05-10-2012
20090324570Photostabilization of Retinoids with Alkoxycrylene Compounds - The photostabilizing electronic excited state energy—particularly singlet state energy from retinoid compounds—has been found to be readily transferred to (accepted by) α-cyanodiphenylacrylate compounds having an alkoxy radical in the four (para) position (hereinafter “alkoxycrylenes”) on one of the phenyl rings having the formula (I):12-31-2009
20090010908Materials and Methods for Diagnosis and Treatment of Chronic Fatigue Syndrome - The invention relates to materials and methods for diagnosis and treatment of chronic fatigue syndrome/myalgic encephalitis. A number of genes are identified which are expressed at abnormal levels in patients affected by CFS/ME as compared to normal healthy individuals. These genes include those encoding defensin α1, haemoglobin γ, CXCR4, tubulin beta 1, serine/threonine kinase 17B, HLA DRss4 and prostaglandin D2 synthase. The genes identified provide objective disease markers that may be used in diagnostic tests to support the diagnosis of CFS/ME or for monitoring the effectiveness of therapy. They also provide a rational basis for classifying CFS/ME patients according to the biochemical lesion underlying their symptoms and enable provision of appropriate targeted therapies.01-08-2009
20090010907Dnazymes for Inhibition of Japanese Encephalitis Virus Replication - The present invention relates to synthetic catalytic DNA molecules or DNAzymes which specifically cleave the RNA sequences of the Japanese Encephalitis Viral genome and is useful in treating Japanese Encephalitis infection. The DNAzyme comprises of a chemical modification, a catalytic domain and two hybridizing arms. The DNAzymes are 29-45 nucleotides in length. The 3′ end of the DNAzyme is tethered to a poly-(G)01-08-2009
20090010906PERORAL DOSAGE FORMS TO ACHIEVE A SUSTAINED-RELEASE EFFECT AFTER MEDICAMENT DOSAGE WITH A MEAL - The present invention relates a retard formulation for oral administration together with a meal comprising at least one active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipient(s) as well as an amount of an agent being able to form a gas (hereinafter also referred to as gas forming agent or gas former), which gas forming agent achieves a homogeneous mixture of the active pharmaceutical ingredient, hereinafter referred to as API, with the content of the stomach, hence providing a continuous initial absorption phase of the API.01-08-2009
20080305095Nutritional Drink - A first composition of drink ingredients specifically designed to lower cholesterol that addresses multiple mechanisms including hepatic synthesis and release, intestinal absorption of cholesterol, while, at the same time, including ingredients that mitigate the side effects of the constituents and increase their efficacy by affecting emotional factors that influence compliance such as a sense of well-being and euphoria on the one hand, or an increased overall metabolism and desire for the product stemming from its coloration on the other hand.12-11-2008
20080305094Nutritional Composition for Improving Skin Condition and Preventing Skin Diseases - The present invention pertains to the use of an ingestable composition containing L-carnitine and at least one component having an anti-oxidative activity for stimulating the lipid metabolism in the skin of an individual, which results in an improvement of the general condition of the skin in particular dry, sensible or reactive skin, and in prevention of the occurrence of skin diseases, such as dermatitis. In addition thereto, the present invention pertains also to the use of such a composition for the preparation of a pharmaceutical composition or of a food, in particular a functional food or petfood product, for increasing lipid secretion in sebum, producing a protective sebum layer on the skin.12-11-2008
20120269793PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF HAIR LOSS - Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with hair loss or prostate cancer/prostate hypertrophy are described herein. These select phytoestrogen formulations are preferably composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in non-reproductive tissues including brain.10-25-2012
20080292607Nutraceutical agent for attenuating the neurodegenerative process associated with Parkinson's disease - This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate and/or oxaloacetate, fruit extracts and anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains substances that should attenuate the loss of ATP/toxicity by PD model toxins: 1-methyl-4-phenylpyridinium and rotenone, scavenge hydrogen peroxide/O11-27-2008
20110008305NANO-EMULSION COMPOSITION OF COENZYME Q10 - The present invention provides a nano-emulsion composition of CoQ10 comprising 5 to 20 wt. % of CoQ10, 1 to 5 wt. % of ethanol, 1 to 5 wt. % of lecithin, 20 to 30 wt. % of caprylic/capric glyceride or vegetable oil(s), 10 to 20 wt. % of glycerin, 1 to 15 wt. % of coemulsifier(s) and the balance of water. The present invention also provides a nano-emulsion composition of CoQ10 comprising 5 to 20 wt. % of CoQ10, 1 to 5 wt. % of ethanol, 20 to 30 wt. % of caprylic/capric glyceride or vegetable oil(s), 1 to 25 wt. % of emulsifier(s), 10 to 20 wt. % of glycerin, and the balance of water. The nano-emulsion composition according to the present invention can preferably improve stability, in vivo penetration, absorptiveness and bioavailability of CoQ10.01-13-2011
20110280851Compositions Comprising Cranberry Extract and Methods of Use Thereof - Described herein are compositions that comprise cranberry extract and are potent and low in calories. Methods of preventing or treating infections by administering the described compositions are also provided.11-17-2011
20100003231POLYMERS OF FLUORINATED MONOMERS AND HYDROCARBON MONOMERS - It is provided an implantable device including a polymer blend that contains a polymer formed of fluorinated monomers and hydrocarbon monomers and another biocompatible polymer.01-07-2010
20110280852NITRO FATTY ACIDS - NEUROPROTECTION AND/OR INHIBITION OF COGNITIVE DECLINE - A composition for treating, ameleliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death comprise a fatty acid component enriched for one or more activated fatty acids and a nutraceutically acceptable excipient. A method for treating, ameliorating and/or preventing conditions associated with cognitive decline and/or motor neuron death includes administering a fatty acid component enriched for one or more activated fatty acids.11-17-2011
20110280850Compositions Containing DNA Repair Enzyme And Anogeissus Extract - A topical composition comprising at least one extract from the 11-17-2011
20090010909Novel GPCR and methods of use of the same - The present invention relates to methods of identifying antagonists of GPR22, a G protein-coupled receptor (GPCR) and related compositions and methods. Antagonists of GPR22 are useful as therapeutic agents for the treatment of ischemic heart disease, including myocardial infarction, post-myocardial infarction remodeling, and congestive heart failure.01-08-2009
20100266565Combinational Chemotherapy Treatment - Methods of combination chemotherapy that are effective for treating neoplasia are provided.10-21-2010
20100266564Polyunsaturated Fatty Acid Synthase Nucleic Acid Molecules and Polypeptides, Compositions, and Methods of Making and Uses Thereof - The present invention is directed to isolated nucleic acid molecules and polypeptides of thraustochytrid polyunsaturated fatty acid (PUFA) synthases involved in the production of PUFAs, including PUFAs enriched in docosahexaenoic acid (DHA), eicosapentaenoic acid (EPA), or a combination thereof. The present invention is directed to vectors and host cells comprising the nucleic acid molecules, polypeptides encoded by the nucleic acid molecules, compositions comprising the nucleic acid molecules or polypeptides, and methods of making and uses thereof.10-21-2010
20090297491Compositions containing non-polar compounds - Provided herein are compositions and methods for preparing foods and beverages that contain additives, such as nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.12-03-2009
20100015119EPITHELIUM-IMPROVING AGENT - It is intended to provide an epithelium improving agent which improves the epithelial functions of various organs and, therefore, is usable in growing melanin-pigmented hair, relieving inflammatory symptoms in gingivitis and paradentitis, treating and relieving cold syndrome and bronchial asthma and, moreover, restoring sexual sensibility. An epithelium improving agent which comprises coenzyme Q10, cysteine, vitamins A, C and E and a skin extract of a rabbit inoculated with a vaccinia virus as the main components. In the case of treating gingivitis, paradentitis, cold syndrome and bronchial asthma, loratadine is further added. To an epithelium improving agent which is to be used in stimulating hair growth or restoring sexual sensibility, liquid paraffin and a hydrophilic ointment is further added to give a cream. Thus, the above problem can be solved.01-21-2010
20110293589METHOD OF TREATING VITAMIN B12 DEFICIENCY - A novel method and composition for treating vitamin B12-01-2011
20090202508NEGATIVE REGULATION OF HYPOXIA INDUCIBLE FACTOR 1 BY OS-9 - The present invention discloses that OS-9 interacts with both HIF-1α and HIF-1α prolyl hydroxylases. Overexpression of OS-9 promotes the hydroxylation of HIF-1α, HIF-1α binding to VHL, proteasomal degradation of HIF-1α, and loss of HIF-1-mediated transcription. OS-9 loss-of-function increases HIF-1α protein levels and HIF-1-mediated transcription under non-hypoxic conditions. These data indicate that OS-9 is an essential component of a multiprotein complex that regulates HIF-1α protein levels in an O08-13-2009
20080267941Nutrition Comprising Betaine Against Muscle Wasting - The invention relates to the treatment or the reduction of the incidence of muscle wasting in humans and to a complete nutritional composition patients suffering from muscle wasting comprising betaine and preferably coenzyme Q10.10-30-2008
20090142322Coenzyme Q10 Production in a Recombinant Oleaginous Yeast - Engineered strains of the oleaginous yeast Yarrowia lipolytica capable of co-producing coenzyme Q06-04-2009
20110293588METABOLIC UNCOUPLING THERAPY - A combination of chemical agents reduces reductive stress by limiting the accumulation of high-energy electrons potentially available to the electron transport chain. A method of metabolic uncoupling therapy comprises: analyzing a specific physiologic process involving reductive stress; identifying a plurality of MUT agents that modulate metabolic pathways by influencing electron flux; and formulating a combination of MUT agents that limits the accumulation of high-energy electrons potentially available to the electron transport chain.12-01-2011
20090136473BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id:05-28-2009
20100150895Nutraceutical agent for attenuating the Neurodegenerative process associated with Parkinson's disease - This invention describes a comprehensive nutraceutical designed to antagonize major mitigating factors to the degenerative process associated with Parkinson's disease. The formulation is comprised of a primary base of pyruvate, succinate, α-Ketoglutarate and/or oxaloacetate, niacin/NADH, fruit extracts, anthocyanins, further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The nutraceutical contains all natural substances that should mitigate many of the neurodegenerative processes known to be associated with PD. Mechanisms addressed are to prevent the loss of ATP/by 1-methyl-4-phenylpyridinium rotenone, scavenge hydrogen peroxide/O06-17-2010
20120189600COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES - The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.07-26-2012
20110217277DRUG OR DERMATOLOGICAL COMPOSITION CONTAINING AN AVOCADO PEPTIDE EXTRACT FOR TREATING AND PREVENTING PRURITUS - The invention relates to a drug or a dermatological composition containing an avocado peptide extract for treating and/or preventing pruritus, in particular gravidic pruritus, pruritus sine materia, pruritus in newborns, and pruritus originating from a drug.09-08-2011
20110217276COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF PRIMARY HEADACHE AND MIGRAINE - Compositions for the prevention and treatment of primary headache and migraine containing pentacyclic diterpenes obtained from 09-08-2011
20090130077SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I:05-21-2009
20100111919DELAYED GELATION COMPOSITIONS AND METHODS OF USE - Biocompatible compositions are provided which may include at least one polysaccharide, at least one salt, and at least one reactive component. The at least one polysaccharide, at least one salt, and at least one reactive component may be in a single solution or multiple solutions and combined utilizing means within the purview of those skilled in the art. The compositions of the present disclosure experience delayed gelation, permitting their manipulation after application to tissue, which may be desirable for certain surgical and/or medical procedures, including cosmetic surgery.05-06-2010
20090130075ENERGY GENERATING COMPOSITION - The present invention is drawn to an ephedra- and artificial stimulant-free energy promoting composition, comprising effective amounts of a magnesium amino acid chelate, a B vitamin, a pyruvate salt, and rhodiola. These ingredients work synergistically together to provide energy, without the use of artificial stimulants, caffeine, or ephedrine. Additional amino acid chelates can also be present, such as iron amino acid chelate, zinc amino acid chelate, copper amino acid chelate, manganese amino acid chelate, chromium amino acid chelate, and mixtures of second amino acid chelates.05-21-2009
20090130078Treatment for Cardiovascular Disease - This invention relates to a method for treating and preventing hypertension by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment. Additionally, the scope of the invention includes a method of treating coronary heart disease by administering a therapeutically effective amount of an agent capable of reducing uric acid levels in a patient in need of such treatment.05-21-2009
20090148426COMPOSITION FOR LIFE EXTENSION AND METHOD OF EXTENDING THE LIFE - The present invention relates to a composition for life extension, comprising reduced coenzyme Q06-11-2009
20090148427PLATELET GLYCOPROTEIN IB ALPHA FUSION POLYPEPTIDES AND METHODS OF USE THEREOF - The present invention provides compositions and methods for treating or preventing vascular-associated disorders.06-11-2009
20120141448Method for increasing muscle mass and strength - Phosphatidic acid is administered orally to increase muscle mass and strength in exercising mammals. Phosphatidic acid is administered orally to aging, bedridden or cachectic patients to improve nitrogen balance. The preferred form of phosphatidic acid for administration is phosphatidic acid-enriched lecithin. Creatine is co-administered orally to increase the muscle-building and strength effect. Other suggested additives include nutritional and herbal supplements, micronutrients and hormones.06-07-2012
20100086531METHODS OF MODULATING PROTEIN HOMEOSTASIS, METABOLIC SYNDROME, HEAVY METAL INTOXICATION AND Nrf2 TRANSCRIPTION FACTORS - Phthalazinediones that function as intracellular redox modulators in the redox therapy of certain stressed cells are provided. By buffering aberrant redox states, phthalazinediones enable cellular processes essential for survival and augment medical treatments. The phthalazinediones of the invention can modulate functions related to cell growth, differentiation, activity, or death, to correct aberrations and restore homeostasis, and can serve as adjunctive therapy in treating various disease conditions.04-08-2010
20110027247METHODS FOR TREATMENT OF ONCOLOGICAL DISORDERS USING AN EPIMETABOLIC SHIFTER (COENZYME Q10) - Methods and formulations for treating oncological disorders in humans using Coenzyme Q10 are described.02-03-2011
20090087420STABLE SOLUTION OF REDUCED COENZYME Q - The present invention provides a composition of a practically usable solution capable of stably maintaining, against oxidation, reduced coenzyme Q, which has not been employed in practice so far because of being liable to undergo oxidation and hydrophobic, a method of preparing the solution and a method of storing the solution. A solution of reduced coenzyme Q which can be stored at a low temperature or room temperature over a long time can be prepared by coating reduced coenzyme Q with liposome made of refined soybean lecithin, etc, and solubilizing, or solubilizing or emulsifying reduced coenzyme Q by using a surfactant at a low temperature.04-02-2009
20090087419LICORICE POLYPHENOL PREPARATION - This invention provides a highly concentrated licorice polyphenol preparation with high bioavailability. Further, this invention is intended to maintain high transparency of a composition without deterioration of the indigenous properties of an aqueous substance, even when such composition is added thereto. Such licorice polyphenol preparation comprises a hydrophobic licorice extract comprising licorice polyphenol as a primary component, medium-chain fatty acid triglyceride, and polyoxyethylene sorbitan fatty acid ester, and the ratio of the total weight of the hydrophobic licorice extract and medium-chain fatty acid triglyceride to the weight of polyoxyethylene sorbitan fatty acid ester is between 1:1 and 1:10.04-02-2009
20100080785DRIED FORMULATIONS - The present invention provides novel formulations with improved bioavailability for substances such as ubiquinone, ubiquinol and omega-3 fatty acid. The present invention provides methods and compositions for drying formulations of such substances, wherein those dried formulations can readily be dissolved in water. The compositions and methods of the invention are of particular use in adding nutrients, such as vitamins and minerals, to food products such as beverages.04-01-2010
20120107295Methods and Compositions for Detecting Pancreatic Disease - Methods and compositions for at least determining whether a human subject has a pancreatic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a pancreatic glycoprotein (GP2) analyte to determine whether the subject at least has the pancreatic disease. Also provided are kits, systems, and devices for practicing the subject methods.05-03-2012
20100098677Methods and Devices for Epithelial Protection During Photodynamic Therapy - Methods for preventing damage to the epidermis during PDT induced using a pre-photosensitizing agent are provided. The methods of the present invention utilize spatial confinement to control formation of a photoactive species from a topically-applied pre-photosensitizing agent. In one embodiment, thermal inhibition is used to prevent the metabolism of a pre-photosensitizing agent in epithelial tissue surrounding a treatment site. In another embodiment, a chemical inhibitor can be applied to the epithelial tissue to inhibit the conversion of a pre-photosensitizing agent into a phototoxic species.04-22-2010
20090142324OIL-IN-WATER TYPE EMULSION CONTAINING COENZYME Q10 AND PROCESS FOR PRODUCING THE SAME - To provide an oil-in-water emulsion composition that prevents separation of coenzyme Q06-04-2009
20100098678Methods of Treatment of Mitochondrial Disorders - In accordance with the present invention, there are provided methods for the treatment of mitochondrial disorders. Invention methods include the administration of a pyrimidine-based nucleoside such as triacetyluridine, or the like. Also provided are methods of reducing or eliminating symptoms associated with mitochondrial disorders. Mitochondrial disorders particularly appropriate for treatment include those attributable to a deficiency of one or more pyrimidines.04-22-2010
20090047265COMPOSITIONS OF PROKARYOTIC PHENYLALANINE AMMONIA-LYASE AND METHODS OF TREATING CANCER USING COMPOSITIONS THEREOF - The present invention is directed to phenylalanine ammonia-lyase (PAL) variants produced by prokaryotes, wherein such prokaryotic PAL variant has a greater phenylalanine-converting activity and/or a reduced immunogenicity as compared to a wild-type PAL. The invention provides compositions of prokaryotic PAL and biologically active fragments, mutants, variants or analogs thereof, as well as methods for the production, purification, and use of such compositions for therapeutic purposes, including the treatment of cancer.02-19-2009
20110200573Methods of inhibiting retrovirus replication and infectivity - The present invention provides methods of inhibiting a retrovirus replication or infectivity by administering a therapeutically effective amount of MOV10 or a fragment, derivative or analog thereof or an inhibitor of MOV10 or a fragment, derivative or analog thereof or of inhibiting a retrovirus replication or infectivity by increasing or decreasing transcription, translation or biological activity of MOV10 or a fragment, derivative or analog thereof. In some instances the retrovirus is HIV or HIV-1. The present invention also features methods of treating a disease caused all or in part by a retrovirus, such as HIV or HIV-1, by administering a therapeutically effective amount of MOV10 or a fragment, derivative or analog thereof or an inhibitor thereof or by increasing or decreasing transcription, translation or biological activity of MOV10 or a fragment, derivative or analog thereof. Further, the present invention features methods to identify an agent that may inhibit a retrovirus comprising identifying an agent that is regulated by MOV10 or a fragment, derivative or analog thereof.08-18-2011
20090202507Intelligent Nanomedicine Integrating Diagnosis And Therapy - A method of controlling the activity of a biologically active compound. The method concerns an oligonucleotide-based compound, comprising a hairpin-forming oligonucleotide, an effector moiety physically associated with the oligonucleotide, where the effector moiety possesses a biological activity, and a regulating moiety physically associated with the oligonucleotide, where the regulating moiety controls the biological activity of the effector moiety by interacting with the effector moiety. The oligonucleotide can assume a hairpin configuration, where the effector and regulating moieties interact, or an open configuration, where the effector and regulating moieties fail to interact. Depending on the nature of the effector and regulating moieties, either configuration can result in the expression of the biological activity of the effector moiety.08-13-2009
20090274674Heterocyclic Oxime Compounds, Process for Their Preparation and Pharmaceutical Compositions Containing Them - Compounds of formula (I):11-05-2009
20090142323METHODS FOR TREATING A DISORDER BY REGULATING GPRC6A - A disorder related to a non-genomic androgen response or a metabolic syndrome can be treated, inhibited, and/or prevented by regulating an expression level and/or activity of GPRC6A. Such a method can include identifying an individual with a disorder associated with a non-genomic androgen response or metabolic syndrome; and administering to the individual in need thereof an agent capable of regulating an expression level and/or activity of GPRC6A thereby treating the disorder associated with the non-genomic androgen response or metabolic syndrome. The regulation of GPRC6A can increase or decrease the concentration of a sex hormone within said individual, as needed for a particular disease. Such regulating can also be used to treat, inhibit, or prevent the symptoms of such a disease.06-04-2009
20090274676COMBINATION OF DEHYDROEPIANDROSTERONE OR DEHYDROEPIANDROSTERONE-SULFATE WITH A PDE-4 INHIBITOR FOR TREATMENT OF ASTHMA OR CHRONIC OBSTRUCTIVE PULMONARY DISEASE - A pharmaceutical or veterinary composition, comprises a first active agent selected from a dehydroepiandrosterone and/or dehydroepiandrosterone-sulfate, or a salt thereof, and a second active agent comprising a phosphodiesterase-4 inhibitor for the treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases. The composition is provided in various formulations and in the form of a kit. The products of this patent are applied to the prophylaxis and treatment of asthma, chronic obstructive pulmonary disease, or other respiratory diseases.11-05-2009
20090004166Carrier For Enternal Administration - There is provided a carrier for use in enteral administration of biologically active compounds, said carrier comprising an effective amount of one or more phosphate derivatives of one or more electron transfer agents.01-01-2009
20110171188NON-THERMAL PLASMA FOR WOUND TREATMENT AND ASSOCIATED APPARATUS AND METHOD - The invention relates to a non-thermal plasma for treatment of a surface, particularly for the treatment of a wound (07-14-2011
20090274677ANTIOXIDANT FOR USE IN COSMETIC, MEDICATED AND PHARMACEUTICAL PREPARATIONS - The invention provides the use a 2,2-dimethyl chroman as a SOD mimetic in a cosmetic preparation. Cosmetic preparations comprising a 2,2-dimethyl chroman as a SOD mimetic are described, as well as methods for treating or preventing free radical damage to skin cells and treating or preventing hair loss which comprise topical administration of a 2,2-dimethyl chroman as a SOD mimetic.11-05-2009
20100061969DIETARY SUPPLEMENT, ANTI-FATIGUE AGENT OR PHYSICAL ENDURANCE ENHANCER, FUNCTIONAL FOOD, OR COSMETIC - Provided is an anti-fatigue agent or a physical endurance enhancer or a functional food having an anti-fatigue effect or a physical endurance-enhancing effect. Specifically provided are: a composition comprising phosphatidylinositol and coenzyme Q10; an anti-fatigue agent or a physical endurance enhancer comprising phosphatidylinositol and coenzyme Q10 as active ingredients; a functional food having an anti-fatigue effect or a physical endurance-enhancing effect, which comprises the compounds as active ingredients; use of phosphatidylinositol and coenzyme Q10 for the preparation of a composition having an anti-fatigue effect or a physical endurance-enhancing effect; and a method of enhancing an anti-fatigue effect or physical endurance, which includes ingesting a composition comprising those compounds as active ingredients.03-11-2010
20100135977COMPOSITIONS AND METHODS FOR TREATING METABOLIC DISEASES - A pharmaceutical composition for treating a metabolic disease in a mammalian subject includes a therapeutically effective amount of all-trans-13,14-dihydroretinoid, all-trans-13,14-dihydroretinoid derivative, or agent capable of modulating the level of at least one all-trans-13,14-dihydroretinoid or all-trans-13,14-dihydroretinoid derivative in the subject.06-03-2010
20090297493 NANOPOROUS PARTICLE WITH A RETAINED TARGET - Porous nanostructured materials, such as porous nanostructured liquid and liquid crystalline particles or materials, incorporate a target substantially within the material which selectively binds a chemical of interest, which can diffusion within the porous nanostructured material and be bound by the target. The porous nanostructured materials can be dispersed as particles in a medium in which said chemical of interest is located with low turbidity. Markers which detect binding of said chemical of interest can be maintained in the medium separate and apart from the target, and any active compound (e.g., an enzyme) associated therewith by the porous nanostructured material, such that detectable changes in the marker only result when the active compounds diffuse out of the porous nanostructured materials after the chemical of interest binds to the target.12-03-2009
20080292606Pharmaceutical Oral Dosage Form Comprising a Non-Steroidal Anti-Inflammatory Drug, and Having Good Palatability - Oral pharmaceutical dosage form comprising tromethamine and a NSAID selected from the group comprising ibuprofen, naproxen and flurbiprofen, characterized in that it also comprises a compound selected from the group comprising glycine, vitamin B6 and mixtures thereof.11-27-2008
20100284983COENZYME Q10-CONTAINING WATER-SOLUBLE COMPOSITION AND PROCESS FOR PRODUCTION THEREOF - A coenzyme Q11-11-2010
20080286255TREATMENT FOR EYE DISORDER - The present invention relates to altering the physical and/or chemical properties of at least part of at least one tissue in the eye. In a specific embodiment, it relates to the treatment of any eye disorder, although in particular embodiments the individual has a thickened Bruch's membrane. An activating energy source is utilized to effect a controlled diffusion enhancement and/or degradation of Bruch's membrane that enables improved diffusional transport between the choroid and retina. The individual is administered an inactivated diffusion-enhancing molecule that becomes associated with the membrane, which is then precisely exposed to an activating energy source, such as light or ultrasound.11-20-2008
20080226616Emulsifier Combination for Cosmetics - The present invention relates to a cosmetic preparation containing an emulsifier combination of polyacrylic acid salts, acrylate/C10-30 alkyl acrylate crosspolymer and carrageenan and the use of the cosmetic preparation.09-18-2008
20090155234DETECTION OF MUTATIONS IN A GENE ASSOCIATED WITH RESISTANCE TO VIRAL INFECTION, MX1 - A method for detecting a mutation related to the gene encoding MxA. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human MxA, including antisense oligonucleotides, methods, and compositions specific for human MxA, are also provided.06-18-2009
20090162335MELATONIN AND IMMUNOSTIMULATING SUBSTANCE-BASED COMPOSITIONS - The present invention relates to synergistic associations of melatonin and other active substances and cosmetic compositions suitable for treating all those manifestations causing or accompanying the aging of skin, hair and other tissues. In particular, the invention is based on the use of melatonin associated with immunoactive and antioxidant substances significantly potentiating its antiaging activity, remarkably reducing free radical formation and thereby improving the aspect of both skin and hair.06-25-2009
20120070422Method of Treating Ocular Disorders - A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).03-22-2012
20130121981Vitamin C Composition for Use in the Prevention and Treatment of Stretch Marks, Radiation Dermatitis, and Other Skin Conditions and Methods of Using the Same - A formulation for a stable ascorbic acid composition which, in a simplified form, is comprised of ascorbic acid in solution with a hygroscopic compound (i.e., a substance with the ability to attract water molecules from the surrounding environment through either absorption or adsorption). Also disclosed herein are methods for the production of such compounds and methods of using such compounds in the prevention, inhibition and treatment of striae gravidarum, radiation dermatitis, rhytids, lentigoes, dyschromia, sun-damage induced hyperpigmentation, cellulite, scars, purpura, skin firming, muscle, tendon and ligament improvement and repair, and hair conditions, among other skin diseases or conditions.05-16-2013
20090252716METHODS FOR IDENTIFYING NUCLEAR RECEPTOR/LIGAND COMBINATIONS FOR TARGETING BRAIN TUMOR STEM CELLS AND FOR THEIR USE - An in vitro method is provided for identifying nuclear receptors abnormally expressed by brain tumor stem cells and a corresponding ligand which, if administered to brain tumor stem cells (BTSC's), is capable of inhibiting cell proliferation. Once the nuclear receptor/ligand combination has been identified, it can be utilized in vitro and in vivo to inhibit the proliferation and survival of the cancerous stem cells and ultimately affect proliferation and survival of tumors. The method can be utilized alone or in combination with other treatment methods. The method can also be utilized with regard to other forms of cancer which have cancerous stem cells associated therewith and which abnormally express one or more nuclear receptors.10-08-2009
20090081178Phenolic Binding Peptides - The present application relates to peptides which bind to tannin, polyphenolic or anthocyanin compounds, and particularly to tea and wine stains on a fabric or other surface. The invention also concerns binding peptide conjugates which includes a binding peptide coupled to an agent and the use of the binding peptide conjugate for delivering an agent to a desired target.03-26-2009
20090098098ANTI-BACTERIAL, ANTI-VIRUS, AND ANTI-FUNGUS COMPOSITION, ITS PREPARATION AND USE - The present invention relates to an anti-bacterial, anti-virus, and anti-fungus composition, its preparation and use. The composition of the present invention mainly includes the following three ingredients in an adequate ratio: (A) a metal compound having a catalytic function; (B) a mixture of a coenzyme having reducing ability and quinones, and (C) an additive. The anti-bacterial, anti-virus, and anti-fungus composition of the present invention is capable of destroying viruses as well as killing bacterial and fungi. Therefore, the composition can be formulated as an aerosol and a film for applying to protection devices such as respirators, masks, gloves, filters, condoms, etc. The present composition can also be used in household, vehicle, hospital, school, restaurant, hotel, internet coffee shop for applying to filter of air-conditioner, tap, stool, interior of elevator and its keyboard. Additionally, the present composition can be applied to human being such as applying to hand, foot, genital organs, oral cavity, and the like in a lower dose to attain the effect of destroying of bacteria, viruses, and fungi.04-16-2009
20090081179METHOD FOR REDUCING THE SEVERITY OF NEUROLOGICAL DISORDERS - The present invention relates to the use of 03-26-2009
20090081177Methods and compositions for improving pregnancy outcome - A method of increasing pregnancy rate in a female subject is provided, the female subject or an oocyte for introduction into the female subject being fertilized by a sperm from a male subject. The method includes the steps of administering to the male subject prior to fertilization: (i) an effective amount of an anti-oxidant agent; and (ii) an effective amount of an agent that reduces inflammation in the male reproductive tract and/or an effective amount of an agent that increases testicular testosterone concentration.03-26-2009
20110142815COMPOUNDS, COMPOSITION, METHODS, TARGETS FOR CANCER THERAPY - This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.06-16-2011
20090098096AGENT FOR CORRECTING STRESS-INDUCING NEURO-MEDIATOR, NEURO-ENDOCRINE AND METABOLIC DISTURBANCES AND METHOD FOR PREVENTING AND TREATING CONCOMITANT PATHOLOGICAL CONDITIONS - The invention relates to medicine, in particular to pharmacology, and is embodied in the form of an agent for limiting neuro-mediator, neuro-endocrine and metabolic disturbances generating the disorders of a central nervous system and functional somatic disorders. The inventive agent is based on a DSIP (delta sleep inducing peptide) or a derivative chemically related thereto and can be used for correcting and preventing functional shifts in a central nervous system and concomitant somatic disorders caused by unfavourable and extreme environmental factors and different pathological conditions of an organism or during the ageing thereof. The inventive method for preventing and treating stress states with the aid of the inventive agent is characterised in that the inventive compositions can be administrated: intranasally in the form of intranasal drops or spray; sublingually in the form of resorbable tablets and capsules; in the form of powders, suppositories, ointments and creams; in the form of different injections (intracutaneous, hypodermic, intramuscular, and intravenous); in the form of different cosmetic agents (creams, lotions, tonics, cosmetic milk, foam, soap, etc.) and in the form of infant food components.04-16-2009
20090098097COMPOSITION FOR NORMALIZING BLOOD PRESSURE - The present invention aims to provide a composition suitable for normalizing the blood pressure, which is useful as food, health food, supplement, nutritional supplement, food for specified health uses, food with nutrient function claims, pharmaceutical product, quasi-drug, feed or pet food.04-16-2009
20090004169Nucleic Acids For Inhibiting Hairless Protein Expression and Methods of Use Thereof - The present invention provides DNAzymes and ribozymes that specifically cleave Hairless protein mRNA. The present invention also provides antisense oligonucleotides that specifically inhibit translation of Hairless Protein mRNA. The present invention also provides various methods of inhibiting the expression of Hairless Protein. Finally the invention provides pharmaceutical compositions containing the instant DNAzymes, ribozymes and antisense oligonucleotides as active ingredients.01-01-2009
20090004168Health Enhancement System - A health enhancement system establishing a health enhancement program through which may be provided a group of natural products, vitamins and minerals, amino acids, herbs and essential oils that may be helpful in aiding the body in fighting the growth of cancers and the progression of other diseases and in reducing the negative side effects of cancer and cancer treatment, and other diseases and their treatment. At least one embodiment of the invention involves a packaging system of the group of natural products, vitamins and minerals, amino acids, herbs and essential oils that the health enhancement system may comprise.01-01-2009
20090004167Use of Inorganic Peroxides for Oxygenation of Soil in Order to Prevent Diseases Caused by Anaerobic Agents in Plants - A method for controlling diseases caused by anaerobic agents in plants by at least partially preventing, stopping or reversing the damage caused by the anaerobic agents, comprising treating the plant or the soil in which the plant is growing or will grow with at least one inorganic peroxide. A formulation for the control of such diseases in plants, comprising at least one inorganic peroxide and at least one additive chosen from biological agents, nutrients and their mixtures.01-01-2009
20090208472OIL-IN-WATER EMULSION COMPOSITION CONTAINING LICORICE-DERIVED POLYPHENOL - The present invention provides a licorice polyphenol-containing oil-in-water emulsion composition comprising medium-chain triglyceride, a licorice hydrophobic extract comprising, as a main component, licorice polyphenol in a weight ratio relative to the medium-chain triglyceride of 1-50%, and a polyglycerol fatty acid ester comprised of a fatty acid residue having a carbon number of not less than 14. Since the composition of the present invention is superior in transparency, stable to acid and heat, soluble in water, it can be used for food, drink, pharmaceutical product, quasi-drug, cosmetic and the like, which enables efficient supply of a licorice hydrophobic extract such as licorice polyphenol and the like.08-20-2009
20090220477PREVENTION OF MICRONUTRIENT DEFICIENCIES ASSOCIATED WITH COMMON DISABILITIES IN THE OVER 50 ADULT - A micronutrient dosage unit which comprises two or more micronutrients selected from vitamin A, vitamin B09-03-2009
20090246186AGENT FOR IMPROVING NERVOUS SYSTEM CELL FUNCTIONS - The present invention aims to activate neural cells in brain, and further provide a useful composition having an action to protect intracerebral neural cells from external and internal stresses.10-01-2009
20090257997Stable Aqueous Compositions Comprising Bioactive Creatine Species - Compositions containing one or more bioactive forms of creatine which are aqueous compositions in which the one or more bioactive forms of creatine do not appreciably degrade into creatinine. Also are methods for providing various beneficial effects which comprise administering aqueous compositions comprising at least one creating O-phosphate species to a mammalian subject, either chronically or acutely.10-15-2009
20090238808Process for the identification of novel enzyme interacting compounds - The present invention relates to methods for the characterization of enzymes or of enzyme-compound complexes, wherein the enzyme is obtained from a protein preparation with the help of at least one broad spectrum ligand immobilized on a solid support and wherein the enzyme is characterized by mass spectrometry. These methods are useful for the screening of non-immobilized compound libraries, selectivity profiling of lead compounds and mechanism of action studies in living cells.09-24-2009
20100015118SUPPLEMENT FORMULA TO PREVENT AND DETER MUSCLE TRAUMA AND METHOD OF USING SAME - A body supplement and method for improving blood flow, muscle chemistry and/or the oxygenation of muscles, said supplement including cinchona bark or quinine in the range of approximately 0.0010 grams and 4.0 grams per dosage.01-21-2010
20100015117COMPOSITIONS AND METHODS FOR TARGETING A POLYPEPTIDE TO THE CENTRAL NERVOUS SYSTEM - The invention provides a chimeric CNS targeting polypeptide having a BBB-receptor binding domain and a payload polypeptide domain. The chimeric CNS targeting polypeptide can have a BBB-receptor binding domain consisting of a receptor binding domain from ApoB, ApoE, aprotinin, lipoprotein lipase, PAI-1, pseudomonas exotoxin A, transferrin, α2-macroglobulin, insulin-like growth factor, insulin, or a functional fragment thereof. Nucleic acids encoding a chimeric CNS targeting polypeptide are also provided. Further provided is a method of delivering a polypeptide to the CNS of an individual. The method consists of administering to the individual an effective amount of a chimeric CNS targeting polypeptide, said chimeric CNS targeting polypeptide comprising a BBB-receptor binding domain and a payload polypeptide domain. The method also can deliver a polypeptide to the lysosomes of CNS cells.01-21-2010
20100003229Nuclear telomerase reverse transcriptase variant - The present invention is directed to a novel variant of human telomerase reverse transcriptase (S16AhTERT), which displays properties distinct from those of wildtype telomerase reverse transcriptase. Accordingly, the amino acid sequence of S16AhTERT and nucleic acid sequences encoding same are presented herein, as are methods of use thereof.01-07-2010
20100015115COMPOUND PREPARATION FOR QUICKLY REDUCING OXIDATIVE STRESS AND PREPARATION OF THE SAME - The present invention discloses a compound preparation for quickly reducing oxidative stress, which contains small molecules and mineral trace elements that can remove or help removing free radicals, can regulate the function of endocrine and circulatory digestive system, as well as other components that can rebuild inner harmony. The compound preparation is in solid dosage form, preferably effervescent tablet or effervescent granules. The preparative method of the compound preparation is also disclosed. Animal experiment and clinical trial show that the invention has strong effect in reducing oxidative stress and disease prevention.01-21-2010
20120195870PREPARATIONS WITH WOOD EXTRACTS OF LOCUST TREES - The present invention relates primarily to the use of locust tree (08-02-2012
20100040591NATIVE POTATO PROTEIN ISOLATES - The invention relates to a process for native potato protein isolation, to native potato protein isolates, to the use thereof, and to a food product comprising a native potato protein isolate. The invention provides a novel isolation process for obtaining highly pure native potato protein isolates having a glycoalkaloid concentration of less than 150 ppm.02-18-2010
20090274675Migraine tonic - This invention is proposing a combination of a system of migraine headache remedies from non-prescription pharmaceuticals in the form of an aqueous drinkable tonic utilizing as the component foundation the main ingredient Ubiquinone (Co-enzyme-Q10) coupled with one or more of the following non-prescription natural or synthesized pharmaceuticals to include but are not inclusive of Tanacetum Parthenium, or Hypericin and/or Hyperforin, Petasin, Magnesium Citrate, and Riboflavin, the selection of which is determined upon the user and the user's other medications.11-05-2009
20120141446Oral Nutritional Supplement Delivery System - A composition for increasing the bioavailability of nutrients in humans and animals comprising an oil base emulsion into which nutrients selected from the group comprising omega fatty acids, vitamin D, Co Q10, green tea extract, and policosanol are added.06-07-2012
20120195871STABLE AQUEOUS SUSPENSION - An aqueous suspension of a hydrophobic nutrient is disclosed. In particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.08-02-2012
20100260736EGR1 MODULATORS FOR THE TREATMENT OF ALOPECIA - An in vitro method of screening of candidate compounds for the preventive or curative treatment of alopecia includes determination of the capacity of a compound to modulate the expression or activity of the Early Growth Response 1 transcription factor (EGR1), as well as the use of modulators of the expression or activity of this transcription factor for the treatment of alopecia; such method also includes in vitro diagnosis or prognosis of this pathology.10-14-2010
20090297492Method for Improving Cognitive Performance - The present invention provides a method for improving cognitive performance that encompasses all of: sense; perception; recognition; judgment; and action or suppression; and is based on a higher brain function. The method for improving cognitive performance of the present invention includes administering astaxanthin and/or an ester thereof to an individual. The cognitive performance is, for example, at least one selected from the group consisting of judging ability, spatial attention-allocating ability, concentration on the recognition of surroundings, and agility as determined by speed and/or accuracy of a body reaction which requires a higher brain function.12-03-2009
20100215631ANTI-INFLAMMATORY COMPOSITION COMPRISING GLYCINE AND LACTOFERRIN AND THE USE THEREOF - The present invention relates to nutritional or pharmaceutical compositions comprising lactoferrin and glycine with an anti-inflammatory activity suitable for patients with an inflammatory disease.08-26-2010
20100226904ORGANIC CHEWABLE SUPPLEMENT - An organic chewable composition for delivering dietary supplements and pharmaceutical compounds. The chewable composition includes an organic delivery vehicle and an active ingredient. The delivery vehicle may include an organic gummy candy. The active ingredient may include an over-the-counter drug or a prescription drug to provide a desired effect on the user. The active ingredient may also include any combination of nutraceuticals, vitamins, minerals, antioxidants, soluble and insoluble fiber, herbs, plants, amino acids, and digestive enzymes.09-09-2010
20100254962FUNCTIONAL DRINK - The invention relates to a liquid food product as aqueous solution with anti-ageing effect, which comprises resveratrole, citric acid, fructose, black grape polyphenol extract, green tea extract, vitamin E, vitamin C and niacin. A concentrated juice from red, edible soft fruit is present at least in a sufficient amount to impart the taste, and advantageously the colour, of the formulation.10-07-2010
20100239550MUTANT CyaA POLYPEPTIDES AND POLYPEPTIDE DERIVATIVES SUITABLE FOR THE DELIVERY OF IMMUNOGENIC MOLECULES INTO A CELL - The invention relates to mutant CyaA/E570Q+K860 polypeptides suitable for use as proteinaceous vectors for delivering one or more molecules of interest into a cell, in particular into a cell expressing the CD11b receptor. The invention further relates to polypeptide derivatives suitable for eliciting an immune response in a host.09-23-2010
20110059061Bioabsorbable Surgical Composition - Bioabsorbable macromer compositions are provided including a diisocyanate-functional bioabsorbable polymer. In some embodiments, the diisocyanate-functional bioabsorbable polymer can be combined with a functionalized polyol. The resulting bioabsorbable macromer composition can be employed as an adhesive or sealant for medical/surgical uses.03-10-2011
20130216512STABLE AQUEOUS SUSPENSION - An aqueous suspension of a hydrophobic nutrient is disclosed, in particular, the nutrient, in ester form, is combined with a selected dispersion aid and a dispersion agent(s), and then dispersed in an aqueous medium to form the suspension.08-22-2013
20100239551COMPOUNDS AND COMPOSITIONS AS CHANNEL ACTIVATING PROTEASE INHIBITORS - The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating chan-nel activating proteases, and methods for using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSSI1E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.09-23-2010
20100239553METHODS FOR PROMOTING CELLULAR HEALTH AND TREATMENT OF CANCER - Systems and methods are provided herein that provide for promoting cellular health and treatment of cancer, and allied diseases such as diabetes and glaucoma.09-23-2010
20120141447NUTRITIONAL SUPPLEMENT - A nutritional supplement for inhibiting sensorineural hearing loss includes from about 0.25 to about 6.0 wt. % thiamin, from about 0.1 to about 10 wt. % pyridoxiyl-5-phosphate, from about 0.01 to about 10 wt. % folic acid, from about 0.025 to about 4.0 wt. % hydroxycobalamin, from about 1 to about 7 wt. % magnesium, from about 0.25 to about 6.0 wt. % zinc, from about 0.001 to about 0.02 wt. % selenium, from about 0.1 to about 10 wt. % manganese, from about 5 to about 50 wt. % ginger root P.E. 4:1., from about 5 to about 40 wt. % citrus bioflavonoids, from about 2.5 to about 40 wt. % 1-cystine, from about 5 to about 40 wt. % n-acetlyl-1-carnitine, from about 1 to about 40 wt. % alpha lipoic acid, from about 1 to about 40 wt. % coenzyme Q10, from about 1 to about 40 wt. % green tea extract, and from about 1 to about 60 wt. % resveratrol.06-07-2012
20100111917CELL-ADHESIVE POLYELECTROLYTE MATERIAL FOR USE AS MEMBRANE AND COATING - A multilayer polyelectrolyte support material is provided that includes a polyelectrolyte layer and a polyelectrolyte-polyethylene glycol layer adjacent to the polyelectrolyte layer. The support material also includes a ligand conjugated to the polyelectrolyte-polyethylene glycol layer, allowing for attachment of a protein or a cell to the support material with controlled orientation.05-06-2010
20080311100Treatment of Keratinous Dryness With Glycerides - The present invention provides the use of medium chain glyceride(s) as an active ingredient for the preparation of a composition for oral and/or parenteral absorption and intended to prevent and/or treat dry and/or delicate keratinous substances.12-18-2008
20090041739Method for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of inflammatory agents in mammalian cells - The present invention provides novel methods for treating a pulmonary disease state in mammals by up or down regulating indigenous in vivo levels of an inflammatory agent in mammalian cells comprising contacting the mammalian cells with a therapeutically effective amount of an inflammatory regulator, wherein the inflammatory agent is selected from the group consisting of cytokines, transforming growth factor-β, elastase, and white blood cells, and wherein the inflammatory regulator is selected from the group consisting of pyruvates and pyruvate precursors.02-12-2009
200900747381-SUBSTITUTED-3-BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO-CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME - A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D-glycopyranosyl) nitrogen-containing heterocyclic compound represented by the general formula (I), a prodrug thereof, or a pharmaceutically acceptable salt thereof, or a hydrate or a solvate thereof; an SGLT inhibitor containing the same; a pharmaceutical composition containing the same and a combination pharmacy of them. In the formula, A represents an alkylene group or alkenylene group; B represents a single bond, —O—, —S— or —NH—; C represents an optionally substituted aryl or heteroaryl group; Q independently represents a carbon atom which a hydrogen atom or a substituent binds to, or a nitrogen atom.03-19-2009
20090246185CARDIAC DYSFUNCTION-AMELIORATING AGENT OR CARDIAC FUNCTION-MAINTAINING AGENT - An object of the present invention is to provide a highly safe oral composition superior in a cardiac dysfunction-ameliorating or cardiac function-maintaining action. The present inventors have conducted intensive studies in an attempt to solve the aforementioned problems and found that use of, particularly, reduced coenzyme Q10 from among highly safe coenzyme Q affords a composition useful for amelioration of cardiac dysfunction and maintenance of cardiac function. Accordingly, the present invention provides a cardiac dysfunction-ameliorating agent or cardiac function-maintaining agent containing reduced coenzyme Q as an active ingredient, and a pharmaceutical product, a food, an animal drug, a feed and the like, which contain the agent.10-01-2009
20090169533COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES - The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.07-02-2009
20100278797Pharmaceutical Composition and Method for Regulating Abnormal Cellular Proliferation - A method of treating a disease associated with a cell population which proliferates abnormally in a subject is disclosed. The method comprises administering to the subject a therapeutically effective amount of at least one modulator capable of modulating in the cell population a level and/or activity of a polypeptide having an amino acid sequence at least 60 percent similar to SEQ ID NO: 5, as determined using the Standard protein-protein BLAST [blastp] software of the NCBI.11-04-2010
20090110672Angiogenic Tyrosyl tRNA Synthetase Compositions and Methods - The present invention provides an isolated tyrosyl tRNA synthetase (TyrRS) polypeptide variant which comprises (a) a Rossmann fold region or a portion thereof, preferably including an 5 coil; and (b) an anticodon recognition domain or portion thereof, preferably including an 14 coil. Preferably, the 5 coil and the 14 coil have a greater spatial separation in the tertiary structure of the variant compared to the corresponding spatial separation in native human TyrRS. The variant preferably comprises an amino acid residue sequence identity of at least about 50% compared to the amino acid residue sequence of human TyrRS (SEQ ID NO: 3), includes at least one non-conservative amino acid residue sequence of human TyrRS, and preferably presents an exposed ELR motif in the 5 coil on an external portion of the tertiary structure of the polypeptide. A preferred TyrRS protein variant comprises the amino acid residue sequence of SEQ ID NO: 4 or a portion thereof. The proteins and protein fragments of the invention are angiogenic and are useful for stimulating angiogenesis in mammalian tissues.04-30-2009
20090110671AGENT FOR ENHANCHING THE PRODUCTION OF COLLAGEN AND IT'S USE - The present invention has an object to provide a means for durably exerting an action of enhancing collagen-production, and the object is attained by providing a collagen-production enhancer which contains, as an effective ingredient, α,α-trehalose and/or a saccharide derivative thereof, and by a composition incorporated with the collagen-production enhancer to be used for such purpose.04-30-2009
20080248013Coenzyme Q10- Containing Composition - There is provided a coenzyme Q10-09-2008
20100297096AMPHIPHILIC PEPTIDE MATRICES FOR TREATMENT OF OSTEOPOROSIS - The present invention provides methods for prevention, prevention of progression, and treatment of osteoporosis and pre-osteoporotic conditions comprising direct administering to osteoporetic bone of a composition comprising amphiphilic peptides and peptide matrices thereof, useful in promoting biomineralization, local osteoporetic medications and inducing bone repair.11-25-2010
20110117070COMPOSITIONS AND METHODS FOR TREATING HEADACHE - Compositions and methods for the treatment of headaches, such as migraine and cluster headaches, comprising co-administration of a first therapeutic component comprising topiramate and a second therapeutic component comprising a therapeutically effective amount or mixture of one or more therapeutic agents selected from the group consisting of riboflavin, magnesium, coenzyme Q10, petasin, isopetasin, and parthenolide. Also disclosed are methods for increasing the efficacy, and reducing or preventing side effects, of topiramate treatment.05-19-2011
20100303783Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such toxins and methods of treating urogenital-neurological disorders in a mammal using such TVEMPs and compositions.12-02-2010
20110123505METHOD OF PRODUCING REDUCED COENZYME Q10 AND METHOD OF STABILIZING THE SAME - The present invention provides a stabilization method of reduced coenzyme Q05-26-2011
20100310538USE OF R(+)-ALPHA-LIPOIC ACID FOR CRYPTOGENIC NEUROPATHY - The present invention relates to the use of R(+)-alpha-lipoic acid ((R)-5-(1,2-dithiolan-3-yl)valeric acid) and/or of a physiologically acceptable derivative of this compound for cryptogenic neuropathy.12-09-2010
20110008306CREATINE-LIGAND COMPOUNDS AND METHODS OF USE THEREOF - The present invention provides methods of treating creatine responsive states, such as a neurological disorder (i.e., Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis and creatine transporter defect) or a skin disorder, by administering a creatine-ligand compound, alone or in combination with an anti-inflammatory compound, to a subject.01-13-2011
20110008307Cephalotaxine Alkaloid Compositions and Uses Thereof - A method of treatment of a host with a cellular proliferative disease, comprising contacting the host with a cephalotaxine and an antiproliferative agent, each in an amount sufficient to modulate said cellular proliferative disease, is described. In some embodiments, the cephalotaxine comprises homoharringtonine (cephalotaxine, 4-methyl-2-hydroxy-2-(4-hydroxy-4-methyl pentyl)butanediocate ester). Antiproliferative agents of the invention comprise alkylating agents, intercalating agents, metal coordination complexes, pyrimidine nucleosides, purine nucleosides, inhibitors of nucleic acid associated enzymes and proteins, and agents affecting structural proteins and cytoplasmic enzymes.01-13-2011
20110008308Composition for hair, skin, nails - A pharmaceutical composition for use in hair, skin and nail health maintenance, for combined, sequential or simultaneous administration, in any form, via any biological route. In its optimal embodiment the composition consists of a daily intake of 1 tablet that consists of: 5 mcg Vitamin D3, 40 mg Vitamin E (natural source), 60 mg Vitamin C, 8 mg Thiamin (vitamin B1), 4 mg Riboflavin (vitamin B2), 18 mg Niacin (vitamin B3), 10 mg Vitamin B6, 500 mcg Folic Acid, 9 mcg Vitamin B12, 45 mcg Biotin, 40 mg Pantothenic Acid, 12 mg Iron, 75 mg Magnesium, 15 mg Zinc, 200 mcg Iodine, 0.5 mg Manganese, 1 mg Copper, 50 mcg Chromium, 100 mcg Selenium, 10 mg L-Cystine, 2 mg Natural Mixed Carotenoids, 15 mg Grape Seed Extract (95% proanthocyanidins); plus 1 Nutri-dermal softgel capsule that consists of: 300 mg Omega-3 Fish Oil, 6 mg Lutein, 200 mg Starflower Oil, 50 mg Blackcurrant Seed Oil, 4 mg Lycopene, and 5 mg Coenzyme Q10.01-13-2011
20110129453Topical skin composition and method for moisturizing the skin - A cosmetic composition with superior moisturizing benefits comprising from approximately 0.3% to approximately 0.9% by weight of bio-chelated mineral blend comprising silicon, magnesium, copper, iron, zinc, and calcium, and at least approximately 85.0% by weight of a humectant blend. Preferably, the bio-chelated mineral blend comprise 06-02-2011
20100015116Designer Ubiquitin Ligases For Regulation Of Intracellular Pathogenic Proteins - The present invention relates to a designer or recombinant ubiquitin ligase molecule that includes a toxin binding domain that is specific for a toxin active fragment, wherein the toxin active fragment is an enzymatically active fragment of one or more toxins or toxin serotypes; and an E3-ligase domain that comprises an E3-ligase or polypeptide that facilitates E2-mediated ubiquitination of the toxin active fragment. In an embodiment, the composition further includes a delivery system that allow the designer ubiquitin ligase to enter the cell. The present invention further includes methods for treating an individual intoxicated with a toxin by administering the designer ubiquitin ligase of the present invention.01-21-2010
20100008894Process of Screening a Molecule as a Candidate Drug for the Treatment of Bipolar Disorder - The invention relates to a complex formed between the 3′-phosphoadenosine 5′-phosphate and polypeptide in human cells, to the use of pAp or of a molecule which mimics pAp for modulating the activity of poly(ADP-ribose)polymerase and small fragment nuclease in human cells, and to process of screening a molecule as a candidate drug for the treatment of diseases where modulation of at least one of the metabolic activities modulated by pAp is needed such as bipolar disorder or related diseases.01-14-2010
20100239549ALPHA LIPOIC ACID CAPSULE COMPOSITION STABILIZED IN WATER PHASE AND METHOD FOR PREPARING THE SAME - The present invention relates to an alpha lipoic acid capsule composition stabilized in aqueous phase, which can effectively prevent alpha lipoic acid from decomposing due to external environmental conditions, such as water, temperature, light, and the like, and can maintain the stability of alpha lipoic acid from the interaction between the lipoic acid and other materials, which are added together with the lipoic acid when the lipoic acid is applied to cosmetics, foods, or medical supplies, by mixing water-dispersed alpha lipoic acid, a water-insoluble polymer having self-emulsification properties, and a hydrophilic solvent, thus capsulating alpha lipoic acid, and to a method of preparing the same.09-23-2010
20100034796Inhibitors of fatty acid oxidation for prophylaxis and treatment of diseases related to mitochondrial dysfunction - Described are a method and a composition for preventing and/or treating a disease related to mitochondrial dysfunction by inhibiting the fatty acid oxidation of one or more cells of an organism. Particularly, the fatty acid oxidation is inhibited by inhibiting the expression and/or activity of the enzyme Carnitin-Palmitoyl-Transferase-02-11-2010
20090186008FLEA HEAD, NERVE CORD, HINDGUT AND MALPIGHIAN TUBULE NUCLEIC ACID MOLECULES, PROTEINS AND USES THEREOF - The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut and Malpighian tubule proteins; and to compounds that inhibit flea head, nerve cord, hindgut and Malpighian tubule protein activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising proteins, nucleic acid molecules, or protective compounds derived from proteins of the present invention as well as the use of such therapeutic compositions to protect animals from flea infestation. Also included in the present invention is the use of flea head, nerve cord, hindgut and Malpighian tubule proteins to derive inhibitory compounds.07-23-2009
20110177047METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OPHTHALMIC CONDITIONS - The disclosure generally describes methods of preventing or treating ophthalmic diseases or conditions in a mammalian subject, such as diabetic retinopathy, cataracts, retinitis pigmentosa, glaucoma, macular degeneration, choroidal neovascularization, retinal degeneration, and oxygen-induced retinopathy. The methods comprise administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.07-21-2011
20110177046DITHIAZOLIDINE AND THIAZOLIDINE DERIVATIVES AS ANTICANCER AGENTS - There is provided a compound of formula (I): wherein Y has the meaning given in the description. Such compounds are potentially useful in the treatment of disorders or conditions caused by, linked to, or contributed to by, excess adiposity, such as hyperinsulinemia and type 2 diabetes.07-21-2011
20110250191COMPOSITION FOR ENHANCING PHYSICAL PERFORMANCE - This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.10-13-2011
20110081329AMINO ACID COMPOSITIONS - Compositions are described herein that are nutritional supplements that contain free amino acids. These supplements contain a homogenous mixture of free amino acids, wherein the free-form amino acids comprise L-Lysine, L-Valine, L-Tryptophan, L-Phenylalanie, L-methionine, L-Leucine, L-Threonine, L-Isoleucine, L-Arginine, L-Histindine, L-Tyrosine, L-Carnitine, L-Serine, L-Glutamine, Aspartic Acid, L-Proline, L-Glycine, Taurine, L-Cysteine, Gamma-aminobutyric acid (GABA), L-Alanine, L-Glutamic acid, and wherein the composition comprises at least one B vitamin. These compositions are of use to treat disorders associated with a deficiency at least one amino acid, such as soft tissue injury, insomnia, panic attacks, anxiety disorders, eating disorders, anorexia, depression, chronic pain, emotional distress, chemical dependence, alcoholism, and hypoglycemia.04-07-2011
20110081330COMPOSITIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS CONTAINING GUM GHATTI - The present invention relates to compositions containing plant gums and one or more fat-soluble active ingredients, wherein the composition comprises less than 40 weight-% oil, based on the total composition in dry matter. These compositions can be used for the enrichment, fortification and/or coloration of food beverages, animal feed, cosmetics or pharmaceutical compositions. The present invention also refers to the preparation of such compositions. The present invention furthermore refers to a process for the manufacture of a beverage by mixing the compositions with ingredients of beverages. The present invention also refers to beverages obtainable by this process.04-07-2011
20110070211Methods of Treating Cancer Using Galanin Retargeted Endopepidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.03-24-2011
20110070214BACITRACIN METAL COMPLEXES USED AS BLEACH CATALYSTS - Bacitracin, bacitracin derivatives and other oligopeptides, alone or in the form of oligopeptide-metal ion complexes, are shown to be useful as bleach catalysts incorporated in washing and cleaning agents for the cleaning of soiled hard surfaces and textile fabrics. These catalysts may be used in conjunction with hydrogen peroxide or any alternate bleaching agent, or used simply in the presence of atmospheric oxygen to bleach stains. New and novel oligopeptides and their metal ion complexes are disclosed herein, along with methods for the cleaning of hard surfaces and textile fabrics with washing and cleaning agents incorporating these bleach catalysts.03-24-2011
20100310539METHOD FOR MANUFACTURING MESOPOROUS MATERIALS, MATERIALS SO PRODUCED AND USE OF MESOPOROUS MATERIALS - The present invention relates to a new synthetise for the preparation of mesoporous structures including mesoporous materials with chiral morphologies and mesoporous materials with local or surface chirality. The method can be used for manufacturing controlled drug delivery devices, for example for delivery of folic acid, and fluorescent particles.12-09-2010
20080254015Gel Composition of Citrus Complex Carbohydrates Cross-Linked with Cellulose Derivate - A gel for application to a wound, comprising a mixture of citrus complex carbohydrates, a cellulose derivative, a polyol component and water, wherein said citrus complex carbohydrates are cross-linked to said cellulose derivative by an ionic cross-linking agent.10-16-2008
20080254016Composition For Increasing Anti-Oxidation Activity In Blood - The present invention provides a composition capable of maintaining antioxidative activity in blood high by keeping the reduced coenzyme Q10-16-2008
20120171186 METHOD FOR PRODUCING A NUTRACEUTICAL COMPOSITION AND THE NUTRACEUTICAL PRODUCED BY THE METHOD - A method for producing a nutraceutical composition comprising a combination of oil soluble antioxidants derived from an edible oil and water soluble antioxidants derived from a plant extract, wherein the plant extract further provides a natural surfactant; and the nutraceutical composition produced by that method.07-05-2012
20090004170COMPOSITION COMPRISING COENZYME Q10 - The present invention provides a composition superior in water-dispersibility/solubility, workability and tabletability, which contains coenzyme Q10, casein, and a saccharide other than polysaccharides, at a particular ratio. The composition can be utilized for food, food with nutrient function claims, food for specified health uses, nutritional supplement, nutritional product, animal drug, drinks, feed, pharmaceutical product, quasi-drug, cosmetic and the like.01-01-2009
20100034795USE OF L-CARNITINE OR ALKANYL L-CARNITINE FOR THE PREPARATION OF A DIETARY SUPPLEMENT OR MEDICAMENT FOR THE TREATMENT OF CORNEAL DISEASE - Use of L-carnitine and/or one or more alkanoyl L-carnitines or one of their pharmaceutically acceptable salts for the preparation of a dietary supplement or medicament for the treatment of corneal diseases is disclosed.02-11-2010
20090022701Recombinant human CLN2 protein and methods of its production and use - The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein.01-22-2009
20080248014Animal Medicament and Method of Manufacture - A medicament for administration to a non-human animal, wherein the medicament includes at Least partially hydrolysed protein and one or more pharmacologically active substances. In a preferred embodiment, the protein is derived from meat which is hydrolysed using a fruit-derived proteolytic enzyme such as actinidin from kiwifruit which enhances the palatability of the resulting hydrolysate. A method of manufacturing the medicament, and a method of medicating a non-human animal by administering to the animal a medicament are also disclosed.10-09-2008
20080248015METHODS AND KITS FOR CO-ADMINISTRATION OF NUTRITIONAL SUPPLEMENTS - The present invention relates to methods of co-administration of various vitamin and mineral compositions, and in a specific embodiment, comprise co-administering one composition comprising vitamin B10-09-2008
20090324568Colonic Delivery of Adsorbents - Orally administrable, site-specific (colonic), particulate delivery systems including adsorbents are disclosed. When delivered specifically to the colon, they can remove various substances present in, or as they reach, the colon. Methods of treatment using the delivery systems, and methods of preparing the delivery systems, are also disclosed. The particulate delivery systems are based on adsorbent matrices encapsulated into and/or onto particles, which selectively deliver the adsorbents to the colon. Representative drug delivery devices include pectin beads, which can optionally be crosslinked with metal ions such as zinc and/or calcium. The delivery system protects the adsorbent and prevents its adsorbing effect in the upper gastro-intestinal (GI) tract. When the particles are made from pectin, and the beads are administered to the colon, specific pectinolytic enzymes in the colon degrade the pectin, allowing the adsorbent to be released and to be fully active. Antibiotics, toxins, and other absorbable substances present in the colon will then be inactivated by adsorption into or onto the adsorbent.12-31-2009
20090324569BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATORY, CARDIOVASCULAR AND CNS DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula I:12-31-2009
20120201802METHOD FOR PRODUCING REDUCED COENZYME Q10, METHOD FOR STABILIZING SAME, AND COMPOSITION COMPRISING SAME - The present invention aims to provide a component having not only an ability to reduce oxidized coenzyme Q10 and an ability to stabilize reduced coenzyme Q10, but also nutrient, flavor, broad utility and the like, and a utilization method thereof. The present invention relates to a safe and convenient method of producing reduced coenzyme Q10, including reducing oxidized coenzyme Q10 by using, as a component derived from a naturally-occurring substance, which is safe for the body, any one or more components selected from the group consisting of an acerola extract, a tea extract, a rosemary extract, a pine bark extract and a 08-09-2012
20120201801TOPICAL CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.08-09-2012
20120201800Methods and Devices for Sustained In-Vivo Release Of an Active Agent - The present invention includes methods and devices for providing sustained in-vivo release of an active agent to a subject. In some aspects, such release may be achieved by reacting an active agent in-vivo with a depot forming agent in order to form a sustained release active agent depot inside the subject. The depot can then release the active agent over a sustained period of time.08-09-2012
20080267938CARDIAC PHYTO-NUTRACEUTICAL SYNERGISTIC COMPOSITION - A Phytoceutical composition for the prevention and treatment of cardiac affections is provided. A specific combination of extracts of plants and nutraceuticals is provided, based on categorizing plants and nutraceuticals into one of three groups, Energy, Bio-Intelligence, and Organization. Such combinations have synergistic effects, with minimal side effects.10-30-2008
20090136472Use of thiazole derivatives and analogues in disorders caused by free fatty acids - There is provided a use of a compound of formula I,05-28-2009
20090110673METHODS OF REDUCING CELL DEATH FOLLOWING HYPOXIA / REOXYGENATION - Provided are methods of reducing cell death, attenuating a burst of reactive oxygen species, reducing cytotoxicity, reducing intracellular oxidant stress due species in a population of cells following hypoxia by reoxygenating the cells in the presence of a reversible electron transport chain inhibitor or under hypercarbic conditions. Also provided is a method to determine the effectiveness of a reversible electron transport chain inhibitor for reducing cell death in a population of cells.04-30-2009
20080279838Reconstructed Human Mariner Transposon Capable of Stable Gene Transfer Into Chromosomes in Vertebrates - The present invention refers to a gene transfer system for stably introducing nucleic acid(s) into the DNA of a cell by using a member of the human mariner transposases. The invention further refers to this transposase and to transposons used in the inventive gene transfer system, comprising a nucleic acid sequence with flanking repeats (IRs and/or IR/DRs). Furthermore, applications of this gene transfer system are also disclosed such as gene therapy, insertional mutagenesis, gene discovery (including genome mapping), mobilization of genes, library screening, or functional analysis of genomes in vivo and in vitro. Finally, pharmaceutical compositions and kits are also encompassed.11-13-2008
20110256117MANUFACTURING AND USE OF COMPOSITE SCAFFOLDS - The present invention refers to a method of manufacturing a composite scaffold including the surface grafting of the scaffold using gamma-irradiation as well as gamma-irradiation of a polymer contacted with the surface of the scaffold. The present invention also directed to the use of the scaffold for tissue engineering and other applications. The present invention is further directed to a method of culturing cells in a composite scaffold of the present invention and to a three-dimensional porous composite scaffold.10-20-2011
20110165136Novel Herbal Composition for Treatment of Psoriasis and Other Skin Disorders - The invention relates to a herbal composition for the treatment of psoriasis and other skin disorders. The herbal composition comprises the extracts of 07-07-2011
20110027248Sugar Chain-Related Gene and Use Thereof - As a result of dedicated studies, the present inventors succeeded in discovering, for the first time, that fibrogenesis could be suppressed at the physiological tissue level by inhibiting sulfation at position 4 or 6 of GalNAc, which is a sugar that constitutes sugar chains. Furthermore, the present inventors conducted studies using various disease model animals, and as a result, successfully demonstrated that inhibitors of sulfation at position 4 or 6 of GalNAc had therapeutic effects on diseases caused by tissue fibrogenesis (tissue fibrogenic disorders).02-03-2011
20100284986COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF MIGRAINES - A therapeutic composition for preventing migraines is described. The therapeutic composition may include riboflavin, magnesium, feverfew and coenzyme Q10.11-11-2010
20100284985Composition - The present invention provides a composition comprising (a) an antimicrobial compound of the formula (I) wherein R11-11-2010
20110135620PRODRUG ACTIVATION IN CANCER CELLS USING MOLECULAR SWITCHES - The present invention features a novel protein engineering strategy by combining the domains of two independent proteins into a molecular switch. The invention features polypeptides comprising a prodrug activating enzyme and a protein that binds a cancer specific marker, polynucleotides encoding the polypeptides, and molecular switches for converting a prodrug into a toxin, comprising the polypeptides. The invention also features methods for converting a prodrug into a toxin, methods for treating cancer, and methods for making the molecular switches, as well as kits.06-09-2011
20110262418COMPOSITION AND METHODS FOR RELIEF OF NEUROPATHOLOGICAL PAIN - The formulations of the present disclosure alter the perception of pain, especially as experienced by subjects reporting the characteristic features associated with the syndrome known as fibromyalgia. The present disclosure encompasses formulations for the relief of symptoms associated with neuropathy pain, where the formulations comprise orthophosphoric acid, a vegetable oil comprising an esterified mono-unsaturated fatty acid, and folic acid. The formulations can further comprise magnesium citrate, magnesium aspartate, malic acid, L-carnitine, alpha-ketoglutaric acid, co-enzyme Q10, glycerol, inositol, and cholinebitartrate, optionally Q10, and riboflavin to provide a yellow color to the formulation. Another aspect of the disclosure are methods for alleviating neuropathy related pain in subject animal or human, comprising: providing to a subject an effective dose of a formulation comprising orthophosphoric acid, a mono-unsaturated fat, folic acid, and water.10-27-2011
20100297095Porifera-Based Therapeutic Compositions for Treating and Preventing Skin Diseases - Therapeutic compositions and methods for using same for treating skin conditions and diseases are disclosed. Treatable skin conditions and diseases include without limitation acne vulgaris, rosacea, seborrheic dermatitis, eczema (atopic dermatitis), psoriasis, photo-aging and actinic keratosisacne vulgaris, psoriasis, photo-aging and eczema. Therapeutic compositions disclosed are derived from Porifera species, specifically sponges, and more specifically fresh water sponges. One disclosed embodiment is derived from 11-25-2010
20110052556PHARMACEUTICAL COMPOSITION COMPRISING RACETAM AND CARNITINE AND PROCESS FOR ITS PREPARATION - The present invention refers to a pharmaceutical composition comprising racetam and carnitine. Said pharmaceutical composition may further comprise coenzyme Q10 and/or agent associated with mitochondrial and/or metabolic disturbance, such as hypocholesterolemic agent of the statins group, a hypoglycemic agent, or an antiepileptic agent. The invention also includes a method of treatment for mitochondrial disturbances comprising administration of the pharmaceutical composition of the invention.03-03-2011
20100330058CHEWABLE DRUG - A chewable composition for delivering pharmaceutical compounds. The chewable composition includes a drug delivery vehicle and an active pharmaceutical ingredient. The delivery vehicle may include an organic or non-organic gummy candy. The active ingredient may include an over-the-counter drug or a prescription drug to provide a desired effect on the user. In addition to the active pharmaceutical ingredient, the chewable composition may also include any combination of nutraceuticals, vitamins, minerals, antioxidants, soluble and insoluble fiber, herbs, plants, amino acids, and digestive enzymes.12-30-2010
20110256118ANTIOXIDANT-CONTAINING FOOD COMPOSITION FOR USE IN ENHANCING ANTIVIRAL IMMUNITY IN COMPANION ANIMALS - The invention encompasses methods for enhancing the ability of a companion animal to resist and/or overcome viral infections. The methods of the invention include an amount of lipoic acid that is effective in enhancing the antiviral immunity of a companion animal.10-20-2011
20110097315Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-- hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one and salts thereof, useful in the treatment of cancer - This invention relates to the enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-43-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one, prodrugs thereof, and pharmaceutically acceptable salts and solvates of said compounds and said prodrugs, that are useful in the treatment of hyperproliferative diseases, such as cancers, in mammals. The invention also relates to processes for the production of enantiomerically pure or optically enriched (+)- or (−)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one enantiomers from a mixture containing two enantiomers using continuous chromatography. The invention further relates to the L-(+)-tartaric acid or (S)-(−)-1,1′-binapthyl-2,2′-diyl hydrogenphosphate salts of (+)-6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3H-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1H-quinolin-2-one.04-28-2011
20100196342MOOD, MEMORY AND COGNITIVE FUNCTION WITH PYRIDOXAL 5'-PHOSPHATE - This invention relates to improvement of mood, memory and cognitive function with administration of pyridoxal 5′-phosphate. Also provided is the use of pyridoxal 5′-phosphate for the preparation of a medicament for the improvement of mood, memory and cognitive function, and kits comprising pyridoxal 5′-phosphate for the same purpose.08-05-2010
20100080786Phenyl or Pyridinyl Substituted Indazoles Derivatives - A compound of formula Ia:04-01-2010
20100239552Combination Therapies for Treating Metabolic Disorders - This invention is directed to pharmaceutical combinations comprising an antioxidant agent, an anti-inflammatory agent, and optionally at least one other anti-diabetic agent useful for treating metabolic disorders. This invention also encompasses pharmaceutically acceptable compositions comprising an antioxidant agent, an anti-inflammatory agent, optionally at least one other anti-diabetic agent, and at least one pharmaceutically acceptable carrier. The combinations and compositions of this invention are useful as methods for treating metabolic disorders including diabetes, particularly Type I and Type II diabetes, as well as diseases and disorders associated with diabetes, including but not limited to atherosclerosis, cardiovascular disease, inflammatory disorders, nephropathy, neuropathy, retinopathy, β-cell dysfunction, dyslipidemia, LADA, metabolic syndrome, hyperglycemia, insulin resistance, and/or chronic obstructive pulmonary disease in a mammal, particularly a diabetic mammal, and specifically a human patient. This invention is particularly directed to pharmaceutical compositions comprising an lipoic acid, one or more anti-inflammatories selected from the group consisting of diflunisal, diclofenac, dexibuprofen, dexketoprofen, naproxen, and salicylate, and optionally one or more pharmaceutically acceptable carriers. The compositions of this invention are useful as methods for treating metabolic disorders including type II diabetes, insulin resistance, beta-cell dysfunction, and hyperglycemia in a patient, particularly a diabetic patient.09-23-2010
20100189704Dietary supplement enhancing the muscular energy metabolism, comprising an alkanoyl carnitine and ribose - A method for treating myocardial or skeletal muscle anoxia which occurs in coronary or post-infarct disorders or during prolonged physical activity and muscle fatigue. This method comprises the administration of a combination composition comprising (a) an alkanoyl L-carnitine selected from the group consisting of isovaleryl L-carnitine, propionyl L-carnitine or the pharmacologically acceptable salts thereof or mixtures thereof; and (b) ribose or a phosphate derivative thereof07-29-2010
20110189152Combination composition, comprising as active ingredients L-carnitine or propionyl L-carnitine, for the prevention or treatment of chronic venous insufficiency - A combination composition comprising as active ingredients L-carnitine or propionyl L-carnitine, troxerutine, diosmine and hesperidine, useful for the prevention and/or treatment of chronic venous diseases.08-04-2011
20110135619Polypeptides of Alicyclobacillus sp. - Isolated polypeptides are disclosed selected from the group consisting of: 06-09-2011
20110135618METHODS OF TREATING CANCER WITH DOXAZOLIDINE AND PRODRUGS THEREOF - The invention provides therapeutically effective compounds for the prevention and treatment of cancer and pharmaceutical compositions containing these compounds as well as methods of using and administering these compounds. The invention also includes methods of activating a prodrug of these therapeutically effective compounds by the administration of a peptide-directed targeting construct that delivers a prodrug-activating enzyme to a target activation site.06-09-2011
20100028318AGENT FOR RELIEF OR PREVENTION OF XEROSTOMIA - The present invention has its object to provide a safer and highly effective composition capable of relieving or preventing xerostomia. The present invention relates to an agent for relieving or preventing xerostomia comprising an oxidized coenzyme Q and/or a reduced coenzyme Q as active ingredients, a composition containing the agent for relieving or preventing xerostomia in a form of a food product, a health food, a dietary supplement, a supplement, an oral health care product, a medicament, a quasi drug, a pet food, a feed or the like, and a method for treating xerostomia and a method for reducing risks of xerostomia comprising administering the composition.02-04-2010
20120308541PHARMACEUTICAL COMPOSITION FOR TREATING THE GASTROINTESTINAL TRACT - Provided are pharmaceutical compositions for the treatment or prophylaxis of the gastrointestinal tract. One of the pharmaceutical composition includes co-particles of an adsorbent, and one or more carbohydrates. This pharmaceutical composition may be used, for example, in the treatment or prophylaxis of diarrhea, for adsorbing digestive tract microorganisms, for enhancing weight gain, or for enhancing milk production in a mammal. Another pharmaceutical composition can include one or more enzymes and a pH buffer system, wherein the pH buffer system causes an alkalinization of at least a portion of a gastrointestinal tract. This pharmaceutical composition may be used, for example, for increasing milk production in a mammal.12-06-2012
20090104171Metabolic Enhancement Therapy - A Metabolic Enhancement Therapy nutritional supplement for treating symptoms and conditions such as acute anxiety, hyperactivity, panic attacks, confusion, involuntary movements, sleep disorders, mood disorders, depression, anger, seizures, obsessive-compulsive behavior, unregulated fear, panic, neuronal disorders, autism, schizophrenia, attention deficit disorder (ADD), attention deficit hyperactive disorder (ADHD) and neuronally based immunologic disorders by administering to a mammal an effective amount of acetyl-L-carnitine, α-lipoic acid, biotin, vitamin B1, L-glutamine, Vitamin B6, taurine, folinic acid, vitamin B12, trimethylglycine, and L-tryptophan.04-23-2009
20100254961WATER-SOLUBLE ELECTROSPUN SHEET - A water-soluble electrospun sheet, containing a water-soluble base material made of at least one material selected from a group consisting of: high-molecular proteins and decomposition products thereof; cellulose-based polymers; plant-based polymers and decomposition products thereof; vinyl-based polymers; acrylic-based polymers; and water-soluble polysaccharides; is provided. In addition to the water-soluble base material, the sheet may further contain at least one functional component selected from among: emulsifying components; stabilizing components; antimicrobial components; humectant components; skin-whitening components; anti-ultraviolet components; astringent components; keratin-softening components; anti-inflammatory components; and coloring components.10-07-2010
20100291056Pharmaceutical Compositions Comprising Prasugrel and Cyclodextrin Derivatives and Methods of Making and Using the Same - The present invention is directed to pharmaceutical compositions comprising prasugrel and a cyclodextrin derivative, and methods of making and using the same.11-18-2010
20100215632BIOMARKERS OF SIRTUIN ACTIVITY AND METHODS OF USE THEREOF - Provided are methods for monitoring sirtuin modulation in a subject, for example, during therapeutic treatment with a sirtuin modulating compound. The methods involve determining the expression level of one or more sirtuin biomarkers in a biological sample from the subject. Also provided are methods for identifying compounds that modulate the activity of a sirtuin protein using one or more sirtuin biomarkers.08-26-2010
20080317725COMPOSITIONS AND METHODS OF TREATING CHRONIC KIDNEY DISEASE - The invention relates to nutritional compositions and methods of using these compositions for the treatment of renal disease. More particularly, the invention discloses compositions of vitamins, minerals, amino acids, and/or proteins in amounts that can be used to supplement the nutritional deficiencies observed in patients afflicted with renal disease, renal insufficiency, or end-stage renal disease. The compositions of the invention can also be used as nutritional supplements for patients undergoing dialysis therapy or for patients on a restricted diet. In addition, the compositions can be used in combination or alone as a method of treating or managing a subject in the various stages of chronic renal disease, or throughout disease progression.12-25-2008
20090196862High dosage Vitamin D - A preparation containing vitamin D08-06-2009
20090285790METHODS OF TREATING AND DIAGNOSING PARKINSONS DISEASE AND RELATED DYSAUTONOMIC DISORDERS - A method for treating a Parkinson's patient with digestive/pancreatic enzymes involves administering an effective amount of digestive/pancreatic enzymes to an individual having the disorder in order to improve a symptom of the disorder. In addition, a method is provided for determining whether an individual has, or may develop, Parkinson's disease or related dysautonomic disorders and for determining whether an individual will benefit from the administration of pancreatic/digestive enzymes to treat the dysautonomic disorder.11-19-2009
20110150854RIBOSWITCHES, METHODS FOR THEIR USE, AND COMPOSITIONS FOR USE WITH RIBOSWITCHES - It has been discovered that certain natural mRNAs serve as metabolite-sensitive genetic switches wherein the RNA directly binds a small organic molecule. This binding process changes the conformation of the mRNA, which causes a change in gene expression by a variety of different mechanisms. Modified versions of these natural “riboswitches” (created by using various nucleic acid engineering strategies) can be employed as designer genetic switches that are controlled by specific effector compounds. Such effector compounds that activate a riboswitch are referred to herein as trigger molecules. The natural switches are targets for antibiotics and other small molecule therapies. In addition, the architecture of riboswitches allows actual pieces of the natural switches to be used to construct new non-immunogenic genetic control elements, for example the aptamer (molecular recognition) domain can be swapped with other non-natural aptamers (or otherwise modified) such that the new recognition domain causes genetic modulation with user-defined effector compounds. The changed switches become part of a therapy regimen—turning on, or off, or regulating protein synthesis. Newly constructed genetic regulation networks can be applied in such areas as living biosensors, metabolic engineering of organisms, and in advanced forms of gene therapy treatments.06-23-2011
20110070213DERMAL COMPOSITIONS CONTAINING COENZYME Q AS THE ACTIVE INGREDIENT - The present invention provides a composition for dermal application 03-24-2011
20090068162Stationary Phase Antibody Arrays for Trace Protein Analysis - The present invention relates to the identification of trace proteins and biomarkers, e.g., TH-1/TH-2, cytokines, MMPs and angiogenic modulators in tear fluids. The present invention provides an antibody-based stationary phase array assay for simultaneously identifying, detecting and characterizing the distribution of a wide range of bioactive trace proteins in a tear fluid sample. A method for simultaneously identifying trace proteins in a biological fluid sample using a highly sensitive antibody-array assay is provided. The present invention also provides methods and kits for treating, preventing, and diagnosing ocular diseases, disorders or pathological conditions.03-12-2009
20100143318GSTP1 AS TERATOGENIC ALLELE FOR AUTISM AND ASSAYS AND METHODS BASED THEREON - The present invention provides novel markers and assays for autism based on the association of GSTP1 with prevalence for having a child or children with autism or autistic disease. The invention relates to the use and application of GSTP1 as a susceptibility marker and teratogenic allele for autism. In particular the genotype of GSTP1 at amino acids 105 and 114, corresponding to nucleotides 313 and 341 are determined. GSTP1 may be combined with other markers in methods and assays for monitoring, managing, diagnosis, prenatal diagnosis, and assessment of autism. In addition, the present invention discloses a novel method for identifying individuals who are genetically susceptible to have offspring with autism wherein the genotype of GSTP1, alone or in combination with other genetic markers or other indicators of oxidative stress, is determined.06-10-2010
20080260711Detoxifizyme with Activity of Transforming Aflatoxin and the Gene Encodes Thereof - The present invention relates to a detoxifizyme with the activity of transforming aflatoxin and the gene encodes thereof. Inventors firstly isolate and purify a novel protein, named aflatoxin-detoxifizyme (ADTZ), which has the activity of transforming aflatoxin. The primes specify to the ADTZ gene are obtained through purification and sequencing. The gene encoding of ADTZ is cloned from the total RNA of 10-23-2008
20110305681TOPICAL HAIR CARE FORMULATION AND METHOD OF MAKING - A topical hair care formulation and method of making includes combining herbal powders to form a herbal powder mixture. The herbal powder mixture is steeped in an amount of carrier oil for a period of time to form an infused oil. A portion of an amount of olive oil is combined with an amount of biotin and an amount of an organosulfur compound to form a natural mixture. A remainder of the amount of olive oil is combined with the infused oil. An amount of jojoba oil is combined with the infused oil. An amount of rosemary oil is combined with the infused oil. An amount of lavender oil is combined with the infused oil. The natural mixture is combined with the infused oil. The infused oil is settled for a period of time to form the topical hair care formulation.12-15-2011
20090257996DIETARY SUPPLEMENT ENERGY-PROVIDING TO SKELETAL MUSCLES AND PROTECTING THE CARDIO VASCULAR TRACT - Dietary supplements—providing energy and strengthening skeletal muscles and facilitating skeletal muscles ability to sustain prolonged periods of physical activity—containing propionyl-L-carnitine or one of its salts, coenzyme Q10, nicotinamide, riboflavin, pantothenic acid and optionally other components such as amino acids and creatines.10-15-2009
20110070212Methods of Treating Cancer Using Glucagon-Like Hormone Retargeted Endopeptidases - The present specification discloses TVEMPs, compositions comprising such TVEMPs and methods of treating cancer in a mammal using such TVEMP compositions.03-24-2011
20100172890AGMATINE CONTAINING DIETARY SUPPLEMENTS, NUTRACEUTICALS, AND FOODS - The invention is dietary supplements, nutraceutical compositions, medical foods, and animal feeds that have cytoprotective (cell and tissue protection) and health promoting effects. The compositions contain a high dose range of agmatine and nutraceutical acceptable salts thereof as dietary fortification for providing effective long-term cytoprotection and affording for soft stool. The compositions may contain agmatine alone or in combination with other dietary ingredients having health promoting effects. The compositions can be prepared with dietary accepted excipients and compatible forms of carriers, including but not limited to, powders, tablets, capsules, controlled release carriers, lozenges and chewable preparations, liquid suspensions, suspensions in an edible supporting matrix or foodstuff and oral rehydration solutions, to enable consumption of said compositions.07-08-2010
20080267940Methods of making concentrated fibrinogen containing compositions and associated systems for preparing fibrin glue - The present invention is drawn to concentrated fibrinogen compositions and associate methods and use thereof. The concentrated fibrinogen compositions can be produced by adding a sufficient amount of a cationic agent, such as protamine, to a fibrinogen containing fluid to cause the fibrinogen to form a fibrinogen precipitate; collecting the fibrinogen precipitate by a collection means, such as centrifugation; and suspending or solubilizing the fibrinogen precipitate in a liquid vehicle to form a concentrated fibrinogen composition. The concentrated fibrinogen compositions can be incorporated into systems for making fibrin glues and be used in treating wounds.10-30-2008
20110064711COMPOSITIONS CONTAINING COENZYME Q-10 AND AN ANTIOXIDANT - The invention describes compositions of a reduced form of coenzyme Q-10 (CoQ10) or CoQ10 or both and an antioxidant that is an anthocyanin extract, a melanin or a compound having at least one thiol (—SH) group.03-17-2011
20090142321Opthalmic composition - An ophthalmic composition which is prepared by incorporating pyridoxine hydrochloride in combination with chondroitin sulfate and a cellulosic polymer. The composition is reduced or eliminated in eye irritation attributable to pyridoxine hydrochloride.06-04-2009
20080213239FATTY ACID FORMULATIONS AND METHODS OF USE THEREOF - The present invention provides dietary formulations comprising polyunsaturated fatty acids and vitamin E. The present invention further provides methods of treating various conditions, generally involving administering to an individual in need thereof an effective amount of a subject dietary formulation.09-04-2008
20110318321CONTROLLED RELEASE PHARMACEUTICAL OR FOOD FORMULATION AND PROCESS FOR ITS PREPARATION - The present invention relates to a controlled release pharmaceutical or food formulation comprising at least one active pharmaceutical or food ingredient dispersed in a mixture of a glycogen with a polysaccharide, and the process for its preparation. The invention also relates to a slow release system represented by a mixture of a glycogen with a polysaccharide, and its use for the preparation of slow release pharmaceutical or food formulations.12-29-2011
20110318320Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women - The present invention relates to nutritional supplements to be administered to, or to be taken by, women desiring to become pregnant, and pregnant and nursing women. The nutritional supplements of this invention have a unique blend of vitamins, minerals, lycopene, co-enzyme Q10, DHA, docusate (such as docusate sodium), folic acid, and a nutritionally acceptable carrier therefor. The invention includes specific nutritional supplements for the uses set forth above.12-29-2011
20100028317Skin Repair Compositions Comprising Circadian Gene Activators And A Synergistic Combination Of Sirt1 Gene Activators - Compositions and methods for enhancing repair of damaged DNA in skin cells. Topical compositions comprising at least one agent that upregulates circadian gene expression in skin cells and at least one non-circadian agent that delays mitosis in skin cells. Preferably, such compositions comprise one or more keratinocyte clock and per1 gene activators, along with SIRT1 or one or more sirt1 activators. More preferably, the sirt1 activator is a synergistic combination of specific peptidic sirt1 activators and resveratrol. Preferably, such compositions are easy to use, efficacious, cosmetically acceptable, chemically, thermodynamically and light stable, safe for topical use, have little or no side effects, and commercially feasible in a personal care marketplace.02-04-2010
20120207728Epithelium-Improving Agent - It is intended to provide an epithelium improving agent which improves the epithelial functions of various organs and, therefore, is usable in growing melanin-pigmented hair, relieving inflammatory symptoms in gingivitis and paradentitis, treating and relieving cold syndrome and bronchial asthma and, moreover, restoring sexual sensibility. An epithelium improving agent which comprises coenzyme Q10, cysteine, vitamins A, C and E and a skin extract of a rabbit inoculated with a vaccinia virus as the main components. In the case of treating gingivitis, paradentitis, cold syndrome and bronchial asthma, loratadine is further added. To an epithelium improving agent which is to be used in stimulating hair growth or restoring sexual sensibility, liquid paraffin and a hydrophilic ointment is further added to give a cream. Thus, the above problem can be solved.08-16-2012
20120308542Method for Ameliorating or Preventing Arrhythmic Risk Associated with Cardiomyopathy by Improving Conduction Velocity - A method for reducing arrhythmic risk associated with cardiomyopathy by improving conduction velocity, includes administering a composition containing NAD12-06-2012
20120064053Baby Lotion - The skin/body lotion composition of the present invention utilizes all natural plant derived components as a method for conditioning and moisturizing the skin. The invention provides good moisturizing and gives a smooth, soft touch feel upon conditioning of the skin, leaving no oily or greasy residue on the skin and is excellent in stability.03-15-2012
20120003200BIOLOGICALLY ACTIVE FOOD SUPPLEMENT - A biologically active food supplement intended to increase the athletes' muscle mass comprises 01-05-2012
20120207730Methods and Compositions for Treating Viral Hemorrhagic Fever - Disclosed herein are methods and compositions for treating viral hemorrhagic fever in a subject by use of at least one inhibitor or suppressor of oxidase, inducible nitric oxide synthase (iNOS) and apoptosis pathway.08-16-2012
20120207729SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I:08-16-2012
20120009169SELF-FORMING PHOSPHOLIPIDIC GELS - A phospholipid gel is spontaneously formed when combining a first phospholipid, a second phospholipid, and water, wherein the first phospholipid is a neutral phospholipid and the second phospholipid is a negatively charged phospholipid. The first and second phospholipids are of natural origin, semi-synthetic origin, or synthetic origin. Preferably, they are di(C8-C22 acyl) phosphatidyl choline and di(C8-C22 acyl) phosphatidyl glycerol. The total phospholipid concentration is within a range of 6-40% by weight.01-12-2012
20120009168IMPROVED EMULSIFYING SYSTEM FOR NUTRACEUTICAL COMPOSITIONS - The inventive composition allows the solubilization of hydrophobic nutraceuticals in water to produce clear and stable solutions. The hydrophobic nutraceutical is combined with a lecithin and optionally other components to form an oil. Sucrose is dissolved in water and combined with hydrophilic cosolvents. Sucrose fatty acid ester emulsifier is dissolved in the sucrose-cosolvent mixture. The nutraceutical oil is homogenized into the sucrose ester emulsifier solution to form a stable homogenate that can be readily dispersed into an aqueous solution.01-12-2012
20120014934Enhanced Natural Colors - A natural color is concentrated to intensify color range and to provide useful amounts of one or more of anti-oxidant, nutritional, and anti-inflammatory compounds derived from one or more pigment sources. In a preferred embodiment, the pigment source is a fruit, a vegetable, a legume, a spice, algae, or a combination thereof.01-19-2012
20120014935RECOMBINANT HUMAN CLN2 PROTEIN AND METHODS OF ITS PRODUCTION AND USE - The present invention relates to a method for treating a patient having disorder characterized by a deficient amount of functional CLN2 protein in the affected cells, which comprises administering to the patient an amount of CLN2 protein effective to reduce or eliminate the symptoms caused by the deficiency in CLN2 protein.01-19-2012
20120058097COMPOSITIONS INCLUDING A SODIUM CHANNEL BLOCKER AND A B VITAMIN MOLECULE AND METHODS OF USE THEREOF - The invention generally relates to compositions including a sodium channel blocker and a B vitamin molecule and methods of use thereof. In certain embodiments, the invention provides compositions that include a sodium channel blocker and a B vitamin molecule. In other embodiments, the invention provides methods for treating a subject having a psychological disorder, a neurological disorder, a neurodengerative disorder, and/or a disorder associated with pain involving administering to the subject a sodium channel blocker and a B vitamin molecule.03-08-2012
20120064055Methods for Treating Lysosomal Acid Lipase Deficiency in Patients - The present invention provides methods of treating LAL deficiency comprising administering to a mammal a therapeutically effective amount of lysosomal acid lipase with an effective dosage frequency. Methods of improving growth and liver function, increasing LAL tissue concentration, and increasing LAL activity in a human patient suffering from LAL deficiency are also provided.03-15-2012
20120064054PHARMACEUTICAL COMPOSITIONS ACTIVE IN PREVENTING, STABILIZING AND TREATING ALZHEIMER'S DISEASE - The present invention relates to pharmaceutical compositions active in preventing, stabilizing and treating Alzheimer's disease and cognitive dysfunctions related thereto.03-15-2012
20100150894COMPOSITION FOR PREVENTION OF CANCER - The present invention has for its subject to obtain a composition for preventing cancer efficient for preventing cancer or preventing cancer recurred after its therapy, or to obtain a pharmaceutical product, food and drink, and cosmetic having a function for preventing cancer.06-17-2010
20120156185NUTRITIONAL COMPOSITIONS COMPRISING CITRUS FIBERS - The present invention provide edible compositions comprising soluble and insoluble dietary fibers at a ratio of about 1:1 ratio, having a palatable taste, useful for reducing the serum lipid content in a mammal, and further for reducing the blood glucose level, enhancing the feeling of satiety and keeping a desired body weight.06-21-2012
20080219962Method to Enhance the Bone Formation Activity of Bmp by Runx2 Acetylation - The present invention relates to a method to enhance the activity of Runx2, a major target protein of Bone Mophogenetic Protein (BMP), by Runx2 acetylation, more precisely, a method to activate BMP-mediated bone formation pathway by protecting Runx2 from ubiquitination, indicating that Runx2 is protected from degradation by the increase of Runx2 acetylation making the protein more stable. The method to enhance Runx2 activity of the present invention can be utilized for the prevention and the treatment of bone disease such as osteoporosis, osteogenesis imperfecta, periodontal disease and fracture, by inducing bone formation by inhibiting Runx2 degradation.09-11-2008
20110091435PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF HAIR LOSS - Select phytoestrogen pharmaceutical compositions and methods of use for preventing or reducing one or more symptoms associated with hair loss or prostate cancer/prostate hypertrophy are described herein. These select phytoestrogen formulations are preferably composed only of two or more plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in non-reproductive tissues including brain.04-21-2011
20100291055SURGICAL HYDROGEL - The invention provides a hydrogel suitable for use in wound healing, particularly for reducing post-surgical adhesions. The hydrogel comprises cross-linked derivatives of chitosan and dextran polymers. The hydrogel forms when solutions of the polymers are combined.11-18-2010
20110104137ADJUNCTS AND COMPLEXES FOR IMPROVING HMG-CoA REDUCTASE INHIBITOR (STATIN) AND SELECTIVE PHOSPHODIESTERASE 5 INHIBITOR THERAPY - Dosage forms and methods of use are disclosed for a) adjuncts administered individually or simultaneously with HMg-CoA reductase inhibitors (statins) and/or selective phosphodiesterase 5 inhibitors or, b) the administration of a conjugate consisting of the adjuncts and an HMG-CoA reductase inhibitor and/or a selective phosphodiesterase 5 inhibitor. The invention is useful in the amelioration of side effects associated with HMG-CoA reductase inhibitors and will improve their effectiveness in diseases for which these are useful. The invention will also improve the effectiveness in the of selective phosphodiesterase 5 inhibitors in patients using these medications alone or in conjunction with statins, for the treatment of erectile dysfunction.05-05-2011
20120121566Solubilized CoQ-10 - The present invention is directed to compositions and methods of delivery of CoQ-10 solubilized in monoterpenes. Use of monoterpenes as dissolving agents, greatly effects the ability to incorporate greater amounts of bioactive CoQ-10 in formulations, such as soft gel capsules.05-17-2012
20100092446DRUG SOLUTION HAVING REDUCED DISSOLVED OXYGEN CONTENT, METHOD OF PRODUCING THE SAME AND DRUG SOLUTION CONTAINING UNIT HAVING REDUCED DISSOLVED OXYGEN CONTENT - It is an object of the present invention to provide a drug solution which has a reduced dissolved oxygen content and is less susceptible to oxidative degradation and highly stable over time, a production method therefor, and a drug solution containing pack which is capable of maintaining the dissolved oxygen content of a drug solution at a reduced level, less susceptible to oxidative degradation of the drug solution and highly stable over time. To achieve the aforementioned object, the reduced-dissolved-oxygen-content drug solution is produced by filling and sealing the drug solution in a drug solution container (04-15-2010
20120121567OPHTHALMIC SOLUTION FOR PROTECTING INTERNAL STRUCTURES OF THE EYEBALL AGAINST UV-A RAYS OR FOR THE TREATMENT OF KERATOCONUS WITH A TRANS-EPITHELIAL CROSS-LINKING TECHNIQUE - An ophthalmic solution containing riboflavin and at least a compound chosen in the group composed of essential and conditionally essential amino acids, coenzyme Q, L-proline, glycine, lysine hydrochloride, L-leucine, L-arginine and compounds intended to stimulate the production of metalloproteinase MMP9 for the protection of internal structures of the eyeball against UV-A rays or for the treatment of keratoconus with a trans-epithelial cross-linking technique.05-17-2012
20120164122PHYTOESTROGENIC FORMULATIONS FOR ALLEVIATION OR PREVENTION OF NEURODEGENERATIVE DISEASES - Select phytoestrogen pharmaceutical compositions and methods of use for promoting neurological heath and prevention of age-related neurodegeneration, such as AD, have been developed. These select phytoestrogen formulations are composed of a number of plant-derived estrogenic molecules and/or their structural analogues and exhibit binding preference to ERβ over ERα and agonist activity in the brain. These ERβ-selective phytoestrogen formulations cross the blood-brain-barrier and promote estrogen-associated neurotrophism and neuroprotections mechanisms in the brain, without activating proliferative mechanisms in the reproductive tissues and are therefore devoid of other estrogen-associated problematic aspects. These are administered enterally, transdermally, transmucosally, intranasally or parenterally, in a dosage effective to prevent or alleviate neuronal damage, effect neuronal regeneration or sustain viability, increase expression of anti-apoptotic proteins, and/or decrease indicators of Alzheimer's Disease.06-28-2012
20100247504POWDER COMPOSITION - A powder composition, includes: (A) an oil-soluble antioxidant substance powder; (B) a water-soluble antioxidant substance powder; and (C) thioctic acid.09-30-2010
20100247505Composition for Reducing the Level of Glucose, Malondialdehyde-Modified LDL, Homocysteine and/or C-Reactive Protein in Blood - Disclosed, is a composition for reducing the levels or level of glucose, malondialdehyde-modified LDL, homocysteine, and/or C-reactive protein in the blood. Specifically disclosed is a composition for reducing the level of at least one substance selected from the group consisting of glucose, malondialdehyde-modified LDL, homocysteine, and C-reactive protein in the blood, which comprises the following components (a) and (b): (a) at least one component selected from the group consisting of vitamin B09-30-2010
20110182872METHODS OF ANALYSIS OF POLYMORPHISMS AND USES THEREOF - The present invention provides methods for the assessment of diseases that result from the combined or interactive effects of two or more genetic variants, and in particular for diagnosing risk of developing such diseases in subjects using an analysis of genetic polymorphisms. Methods for the derivation of a net score indicative of a subject's risk of developing a disease are provided.07-28-2011
20120134976ORAL FORMULATIONS FOR COUNTERACTING EFFECTS OF AGING - An oral formulation as described herein can comprise pomegranate extract, panax ginseng extract, and 05-31-2012
20120171184CELLULAR HYDRATION COMPOSITIONS - A composition interacts with a biological cell system that includes bioactive molecules with biomolecular surfaces, cellular components and water molecules with a specific density. The composition includes a biologically active component that is constructed to increase an activity of a biological cell system by increasing the hydration of one or more components of that cell system. The biologically active component may include a primary carbohydrate clathrate subcomponent that increases the H-bonded structure of water, and a secondary solute subcomponent. The biologically active component may include an inclusion complex that is made up of a clathrate component and a complex-forming compound. The clathrate subcomponent may include amyloses or cyclodextrins. There is also a beverage and a method that improves cellular hydration in an animal, such as a human.07-05-2012
20120171185Formulation and Method for Providing Safe, Clean, Chlorinated Recreational Water - A solid formulation for use with sodium chloride and a chlorine generator to provide safe, clean chlorinated recreational water. The formulation comprises a chlorine stabilizing agent and a phosphate remover agent. An enhanced salt comprising a chlorine stabilizing agent, a phosphate remover agent and sodium chloride is also described. The formulation and enhanced salt can also contain a metal chelating agent and a pH balancing agent. A cleaning agent may also be included. A fast dissolving sodium cyanurate compound is used for the chlorine stabilizing agent. A method, kit, and system for providing safe, clean chlorinated recreational water are also disclosed.07-05-2012
20120213759ANTIMICROBIAL CLEANING AGENT FOR HARD SURFACES - A surfactant-containing aqueous antimicrobially effective cleaning agent for hard surfaces includes at least one amphoteric polymer, a quaternary ammonium compound and formic acid. The agent may be used for the cleaning and/or antimicrobial treatment of hard surfaces, in particular in damp rooms such as bathrooms.08-23-2012
20120213757NUTRITIONAL SUPPLEMENT COMPOSITION - New dietary supplement composition comprising, as active ingredients: 08-23-2012
20120213758BIARYL PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The present invention relates to a genus of biaryl compounds containing at least one further ring. The compounds are PDE4 inhibitors useful for the treatment and prevention of stroke, myocardial infarct and cardiovascular inflammatory diseases and disorders. The compounds have general formula Ia, Ib, Ic or Id:08-23-2012
20120213756NUTRACEUTICAL BEVERAGE - A nutraceutical composition for humans and/or animals containing three main components: water, 08-23-2012
20100047221COMPOSITIONS COMPRISING PYRUVATE ALKYL ESTERS AND USES THEREOF - The present invention provides a composition comprising pyruvic acid alkyl ester for ingestion by a human as a food, oral supplement or pharmaceutical.02-25-2010
20100047222Nucleic acids and polypeptides of C1 bacteriophage and uses thereof - The full-length nucleic acid sequence of the C02-25-2010
20100047223Pharmanutrient Composition(s) and System(s) for Individualized, Responsive Dosing Regimens - Individualized responsive dosing pharmanutrient systems, compositions, methods of dosing, and processes of producing the same, which allow a consumer to generate individualistic biological responses/effects. More specifically, a pharmanutrient system for generating individualized biological conditions/responses which utilizes ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, organics substrates, inorganic or synthetic substrates, biological components, and/or other nutrients incorporated or provided with a pharmacologically active ingredient in a bio-active delivery system which preferably avoids first pass metabolism, such that an individual may take multiple doses of the same or different pharmanutrient based on varying desired biological response within each dosing period.02-25-2010
20120177623Compositions for Boosting Metabolism, Assisting Weight Loss, and Promoting Cardiovascular Health - This invention relates to orally ingested compositions for boosting metabolic rate and reducing or controlling levels of cholesterol and triglycerides and improving cardiovascular function, thus preferably assisting with weight loss and promoting cardiovascular health when administered to mammals, including humans.07-12-2012
20120258087ISOTONIC BEVERAGE WITH CHELATES - The subject of the invention is an isotonic beverage with chelates containing carbohydrates, mineral amino acid chelates, L-carnitine, sweeteners, flavouring substances, and a diluent, the essential feature of the beverage being the content of up to 0.1 wt % of mineral components in the form of mineral amino acid chelates, preferably bisglycinates and glycinates, from 0.1 to 50 wt % of isomaltulose, up to 15 wt % of L-carnitine and/or its derivatives, from 5 to 84% of carbohydrates, up to 50 wt % of bioactive substances, up to 50 wt % of flavouring substances, up to 80 wt % of polyalcohols, diluents, tableting aids, stabilizers, antioxidants, dyes, and 0.013-25 wt % of sweeteners, whereby its osmolarity is 275-295 mOsm/kg and pH is 2-5.10-11-2012
20090060891High Concentration Self-Microemulsifying Coenzyme Q10 Preparations For Nutritional Use - A method and composition are presented for enhancing the dissolution and bioavailable properties of CoQ10 nutritional supplements and/or therapeutic agents for a human being and other mammals. The method includes preparing an anhydrous self-microemulsifying base composition by combining: CoQ10, a water-immiscible, and a non-ionic surfactant, containing polyethylene glycol. For an orally administered CoQ10 nutritional supplement in a capsule formulation, a unit dosage from the composition is added to a dissolvable capsule, preferably a soft gelatin capsule, in order to form the nutritional supplement. When a capsule containing the self-microemulsifying composition enters the digestive tract, the temperature of the body's digestive juices warms the composition, causing any of the CoQ10 that may have re-crystallized out of the composition to become re-dissolved into the composition before the capsule dissolves. The re-dissolution of CoQ10 is bioavailable when the capsule dissolves. Upon dissolution of the capsule, the self-microemulsifying composition comes into contact with the digestive juices and naturally forms micellar-type bioavaible microemulsions, consisting of micelles containing CoQ10. In addition to the capsule formulation, the invention includes parenteral, liquid, topical and ophthalmic formulations.03-05-2009
20090060892AGENTS FOR SUPPRESSING HEPATIC FIBROSIS - The present invention relates to hepatic fibrosis-suppressing agents that are suitable for treating or preventing fibrotic liver diseases such as cirrhosis, which comprise as an active ingredient a substance that inhibits the production or accumulation of chondroitin sulfate proteoglycans including chondroitinase ABC and ADAMTS-4; and methods of screening for the agents.03-05-2009
20130017182MULTI-CRITERIA OPTIMIZED DIETARY SUPPLEMENT FORMULATIONS - Dietary micronutrient supplement formulations for specific ages, gender, special requirements and health conditions comprising, vitamins, minerals, fish and plant oils, amino acids, enzymes, phytochemicals, herb and fruit extracts and other natural compounds grouped into morning, mid-day and evening formulas based on their synergism and antagonism with each other, their interactions with ingredients in the food consumed during each meal and their bioavailability. The dietary micronutrient formulations are optimized to meet the Recommended Daily Allowances (RDA) and Adequate Intake (AI) standards for each segment of the population with larger amounts of nutrients used in condition-specific formulas.01-17-2013
20090130076SUBSTITUTED BENZOAZOLE PDE4 INHIBITORS FOR TREATING PULMONARY AND CARDIOVASCULAR DISORDERS - The invention relates to substituted benzothiazoles, benzoxazoles—and their counterparts having pyridine and pyrimidine rings replacing the benzene ring—that are PDE4 inhibitors useful for treating stroke, myocardial infarct, and cardiovascular inflammatory conditions, to pharmaceutical compositions comprising these compounds, and to methods for the treatment of stroke, myocardial infarct, and cardiovascular inflammatory conditions in a mammal. The compounds have general formula I:05-21-2009
20090214504Methods and Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation - A method for treating a patient suffering from a wound, ulcer, or inflammation includes providing a topical formulation comprising a carrier and a combination of active ingredients that includes at least one retinoid and at least one blood vessel dilator, and applying the topical formulation to the skin of the patient to cause healing, accelerated healing or prevention of the wound, ulcer or inflammation. Additional active ingredients may include a promoter of mitochondrial function or an antioxidant.08-27-2009
20110123507Ultra Low Dose Nutraceutical Compositions for Enhancing Sleep Quality and Treating Sleep Disorders - The present technology relates to a dietary supplement, composition, nutraceutical, and/or system for inducing or treating biological responses or conditions (namely sleep or sleep disorders) which utilize ultra-low dosage amounts of vitamins, minerals, amino acids, co-enzymes, stimulants, and/or similar ingredients in a highly bio-active delivery system which bypasses first pass metabolism. In particular, the present technology relates to a nutraceutical composition/formulation which substantially bypasses first pass metabolism and such as, but not limited to, sleep apnea. Methods of using the composition/formulation to elicit enhanced sleep quality, induce short duration sleep and/or treat sleep disorders are also provided.05-26-2011
20110123506Dietary health food composition, package and method of use - A safe and effective dietary composition and method of use in which the composition contains protein, fat and carbohydrates in ratio of approximately 33% protein, 60% fat and 8% carbohydrates, the fat preferably being monounsaturated (MUFA) and polyunsaturated (PUFA) and providing, preferably, less than 800 calories per day. The preferred method of use includes consumption of a small quantity of this composition on an hourly basis which, preferably, is divided into some 16 equal dosages for the purpose of maintaining a continuous presence of macronutrients in the gastrointestinal tract to stimulate the production of hormones that produce feelings of satiety, a sense of well being and that suppress sensations such as hunger. In addition to this composition and the preferred method of consumption, the dieter may also consume salads that, preferably, provide no more than 250 calories.05-26-2011
20080299100Topical Co-Enzyme Q10 Formulations and Methods of Use - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.12-04-2008
20080299101Cancer Treatment Resistance and Agents Modulating Such Resistance - The present invention concerns a method for detecting in vitro resistance of cancer cells to a treatment by detecting in the cancer cells supernumerary nucleolar organizer regions (NOR), whereby identification of the presence of supernumerary NOR in the cancer cells is indicative of treatment resistance. The present invention also concerns a method for defining the capacity of a candidate agent to modulate NOR genes number of cancer cells by contacting the cancer cells with a candidate agent for a time sufficient to permit modulation of NOR genes number; and observing whether NOR genes number increases or decreases in said cancer cells. The present invention also provides a candidate agent that modulates NOR genes number of cancer cells obtained by the method of the invention and a composition for treating and/or preventing a cancer in a patient, comprising said candidate agent. Such a candidate agent decreases the NOR genes number in said cancer cells.12-04-2008
20110002905COMPOSITIONS OF FAT-SOLUBLE ACTIVE INGREDIENTS CONTAINING PROTEIN-POLYSACCHARIDE CONJUGATES - The present invention relates to compositions containing one or more proteins, one or more polysaccharides and one or more fat-soluble active ingredients and their use for the enrichment, fortification and/or coloration of food beverages, animal feed and/or cosmetics.01-06-2011
20080279837Composition for maintaining androgen and androgen-like uptake potential by cells - A composition comprising at least a therapeutically effective amount of L-carnitine fumarate, and an extract of 11-13-2008
20110033437Debridement Method Using Topical Nitric Oxide Donor Devices and Compositions - The present invention relates to methods for removal of dead tissue from wounds or skin using topical nitric oxide donor devices and/or compositions. In one embodiment, the present invention relates to a transdermal patch device that is designed to deliver nitric oxide. In another embodiment, the present invention relates to one or more devices and/or compositions that are designed to deliver nitric oxide and optionally one or more other compounds, where such devices/compositions include, without limitation, bandages, layered bandages, adhesive bandages, transdermal patches, creams, ointments, or a any combination of two or more thereof.02-10-2011
20110038845Diagnosis and treatment for endometriosis - The invention relates to detection of individuals having or at risk of developing endometriosis based on the presence of one or more polymorphism in a gene associated with the fibrinolytic pathway, and methods for treating or preventing endometriosis by modulating the fibrinolytic pathway.02-17-2011
20120328588COMPOUND PREPARATION AND ITS USES FOR PREVENTION AND TREATMENT OF HEARING IMPAIRMENT - A compound preparation contains alpha-lipoic acid and nimodipine at a ratio from 5:1 to 40:1. The above-mentioned compound preparation can be used for the prevention and treatment of noise-induced hearing impairment. This compound preparation not only increases the efficacy but decreases the dosage of nimodipine, reduces the side effects and improves the patient compliance.12-27-2012
20110044965L-CITRULLINE FOR TREATING ENDOTHELIAL DYSFUNCTION AND ERECTILE DYSFUNCTION - L-citrulline for treatment of endothelial dysfunction and in particular of erectile dysfunction and a pharmaceutical composition comprising L-citrulline in combination with one or more substances selected from the group consisting of pycnogenol, aqueous extract of 02-24-2011
20110044964PLANT-BASED OMEGA CHEWABLE SUPPLEMENT - A chewable composition for the oral delivery of plant-based omega fatty acid compounds. The chewable composition includes a delivery vehicle and an active ingredient incorporated therein. The delivery vehicle may include an organic or in-organic gummy candy made from a binding agent, sweeteners, flavoring, and coloring. The active ingredient may include a plant-based omega fatty acid to provide a desired effect on the user. The delivery vehicle may also include any combination of nutraceuticals, vitamins, minerals, antioxidants, soluble and insoluble fiber, herbs, plants, probiotics, prebiotics, antioxidants, amino acids, digestive enzymes, proprietary dietary supplements, or any other health promoting ingredient.02-24-2011
20120269794NUTRACEUTICAL COMPOSITION THAT COMPRISES EXTRACT OF SHILAJIT, FOLIC ACID, VITAMIN B12 AND VITAMIN B6 AND THE USE THEREOF FOR PREVENTING AND/OR TREATING NEURODEGENERATIVE DISEASES AND/OR THE COGNITIVE DETERIORATION ASSOCIATED WITH CEREBRAL AGEING - The present invention relates to a potent antioxidant neuroprotective nutraceutical composition that comprises blending extract of Shilajit (250 to 500 mg) and folic acid (200 to 400 μg), together with small amounts of vitamins B6 (20 to 40 μg) and B12 (4 to 8 μg) consumed per day. This composition can be used to prevent and to treat neurodegenerative diseases or episodes of cognitive deterioration arising from various pathological conditions. The use thereof is indicated in the treatment of Alzheimer's disease and senile dementia as the pathological conditions preferably to be treated. The composition is suitable for direct human consumption by mouth, either in solid form as a powder or as a suspension of the extract, as a food additive or as a nutraceutical agent. It may be formulated as a nutraceutical agent to be included as an ingredient in beverages or as a drug in conjunction with permitted excipients.10-25-2012
20120269792EUTECTIC-BASED SELF-NANOEMULSIFIED DRUG DELIVERY SYSTEM - A eutectic-based self-nanoemulsified drug delivery system (SNEDDS) is formulated from polyoxyl 35 castor oil (Cremophor), medium chain mono- and diglycerides (capmul), essential oils, and a pharmacologically effective drug. The preferred pharmacologically effective drug is a poorly water soluble drug, such as ubiquinone (CoQ10-25-2012
20100028319COMPOSITION FOR PREVENTION OR TREATMENT OF DIABETES - The present invention aims to provide a composition which has an extremely broad range of applications, has an excellent safety, and can be used for preventing, ameliorating, or therapeutically-treating diabetes.02-04-2010
20110236364Compositions containing non-polar compounds - Provided are compositions and methods for clear and stable beverages that contain additives such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.09-29-2011
20100233145COMPOSITION USED AS A NUTRITIONAL SUPPLEMENT AND MEDICATION FOR THE TREATMENT OF DEGENERATIVE VISUAL DISORDERS AND INFLAMMATION - A composition and a dosing unit which can be used as nutritional supplement or as medication for the treatment of retinitis pigmentosa (RP). The composition comprises a combination of lutein, zeaxanthin, glutathione and alpha lipoic acid, optionally supplemented with an extract of Lucium Barbarum Lynn. This composition inhibits the death of photoreceptors as a consequence of RP, whereby the visual faculties of the patient are retained for a longer time. The composition is also useful as an anti-inflammatory drug.09-16-2010
20080267942BENZAZEPIN-2(1H)-ONE DERIVATIVES - Compounds of formula (I)10-30-2008
20120321603COMPOSITION AND METHOD FOR STABILIZATION AND DELIVERY OF THERAPEUTIC MOLECULES - A composition and treatment method are disclosed for one or more of alpha, beta, and gamma-Cyclodextrin and a natural molecule or fragment thereof wherein the natural molecule is sometimes Glutathione, is non-acetylated, non-Esterified, and non-fatty acid attached, and the composition is administered parenterally and non-interveneously.12-20-2012
20120321602OMEGA-3 FATTY ACID NUTRICEUTICAL COMPOSITION AND OPTIMIZATION METHOD - A novel omega-3 fatty acid/lipid based nutraceutical composition and a method of optimizing said omega-3 fatty acid/lipid based nutraceutical composition. The nutraceutical composition and method is based on the insight that different forms of high omega-3 fatty acid lipids (e.g. triglyceride form, ethyl ester form, free fatty acid form, phospholipid form) have different molecular modes and levels of action. Specifically the phospholipid form is likely more effective at promoting membrane fluidity and permeability, while the free fatty acid form is likely more effective at regulating cell receptors, such as the PPARα receptors, that are responsible for various metabolic effects including lipid metabolism. The desirability of producing omega-3 compositions that may act synergistically and thus more robustly to improve health and to some extent mimic markers of life extension such as shown by caloric restriction, along with specific optimization methods, markers, and compositions are taught.12-20-2012
20120321604CARRIER COMPRISING NON-NEUTRALISED TOCOPHERYL PHOSPHATE - The present invention relates to a carrier for the delivery of a nutraceutical or cosmeceutical active comprising non-neutralised tocopheryl phosphate and a hydrophobic vehicle. The present invention also relates to a formulation comprising the carrier and a nutraceutical or cosmeceutical active.12-20-2012
20100143319KIWIFRUIT COMPOSITIONS - Extracts derived from kiwifruit are particularly useful for managing gut health and for treating or preventing digestive dysfunction and/or gastrointestinal tract disorders. In one aspect the extracts include an effective amount of prebiotic material derived from kiwifruit of the species 06-10-2010
20120100120PERFORMANCE ENHANCING COMPOSITION AND METHOD OF DELIVERING NUTRIENTS - An aqueous composition specifically adapted for supporting physical performance. The liquid composition comprises ribose, a saccharide such as glucose or dextrose, coenzyme Q10, ATP, caffeine, and D-pinitol in conjunction with minerals and electrolytes. The orally-consumed liquid composition may be sold in solid form, such as a powder, granulate, or tablet to be added to water or other fluid, or it may be sold as a shelf-stable ready-to-drink liquid. The liquid composition physiologically enhances essential energy stores and provides a supply of ingredients which support physiological generation and regeneration of ATP.04-26-2012
20120288485USE OF JASMONE FOR MODULATING MELATONIN PRODUCTION AND CALCIFICATION OF THE PINEAL GLAND - A formulation, composition or combination of substances comprising jasmonate for modulating melatonin production and/or calcification of a pineal gland and/or modulation and/or treatment of age-related neurodegeneration in a subject, particularly in a mammalian subject and more particularly in a human subject and use of jasmonate for modulating melatonin production and/or calcification of a pineal gland and/or modulation and/or treatment of age-related neurodegeneration is provided.11-15-2012
20120288486Method for Ameliorating or Preventing Arrhythmic Risk Associated with Cardiomyopathy - A method for reducing arrhythmic risk associated with cardiomyopathy includes administering a composition containing NAD11-15-2012
20100203028ANTIMICROBIAL COMPOSITIONS - An antimicrobial composition is provided having a mole ratio of equivalents of silver ion to equivalents of anion of greater than 1. The invention further relates to antimicrobial compositions composed of silver ions and silver salt particles. Also provided are methods for using the compositions of the invention for the treatment of a subject, and methods for conferring antimicrobial protection to an object.08-12-2010
20100172889DEGRADABLE BIOMOLECULE COMPOSITIONS - This document provides methods and materials related to degradable biomolecule compositions. For example, methods and materials related to compositions having one or more biomolecules and one or more biomolecule degrading enzymes having activity to degrade the one or more biomolecules of the composition are provided. In some cases, the degradable biomolecule compositions provided herein can be used as wound dressings to facilitate wound healing, as tissue scaffolds or tissue matrices to promote tissue growth or tissue regeneration, as bulking agents to provide bulk to tissue in a temporary manner, and as non-medical devices to provide compositions that are degradable.07-08-2010
20130011377COMPOSITIONS, KITS AND METHODS FOR NUTRITION SUPPLEMENTATION - The present invention relates to compositions, kits and methods for the administration of various vitamin, mineral and nutrient compositions, and in a specific embodiment, the compositions, kits and methods may utilize or include vitamin D, iodine, vitamin B1, vitamin B6, vitamin B12, vitamin B2, vitamin B9, vitamin B3, vitamin E, vitamin A, vitamin C, iron, zinc, copper, magnesium, omega 3 fatty acids and one or more pharmaceutically acceptable carriers.01-10-2013
20130017183Compositions containing non-polar compounds - Provided herein are compositions and methods for preparing foods and beverages that contain additives. Additives include nutraceuticals, pharmaceuticals, and supplements, such as essential fatty acids, including omega-3 fatty acids, omega-6 fatty acids, conjugated fatty acids, and other fatty acids; phytochemicals, including phytosterols; other oils; and coenzymes, including Coenzyme Q10, and other oil-based additives.01-17-2013
20090220476LAGLIDADG HOMING ENDONUCLEASE VARIANTS HAVING MUTATIONS IN TWO FUNCTIONAL SUBDOMAINS AND USE THEREOF - Provided is a LAGLIDADG (SEQ ID NO: 50) homing endonuclease variant having mutations in two separate subdomains, each binding to a distinct part of a modified DNA target half-site, the LAGLIDADG (SEQ ID NO: 50) homing endonuclease variant being able to cleave a chimeric DNA target sequence having nucleotides bound by each subdomain. A heterodimeric meganuclease and derived products for genetic engineering, genome therapy and antiviral therapy are also provided.09-03-2009
20110158971COMPOSITIONS COMPRISING N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS AND METHODS OF USE THEREOF - Disclosed are pharmaceutical compositions comprising 6-(4-Bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide, or a pharmaceutically acceptable salt thereof. Also disclosed are methods of using such compositions for inhibiting abnormal cell growth or treating hyperproliferative diseases in mammals.06-30-2011
20130022587Cycloalkyl-Substituted Imidazole Derivative - A compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, wherein A represents a C3 to C12 cycloalkyl group which may be substituted by one to three selected from a fluoro group, a hydroxy group, a C1 to C6 alkyl group, etc; R01-24-2013
20130171119SKIN CARE COMPOSITIONS - Dermatological and cosmetic compositions and methods are provided to reduce the appearance of biological and/or environmentally-caused aging.07-04-2013
20080241119Micronutrient formulations for pulmonary and heart health - A heart and pulmonry health micronutrient formulation is provided and the formulation comprises dietary antioxidants and endogenous antioxidants, and the formulation comprising dietary micronutrients and endogenous antioxidants, the dietary antioxidants are selected from a group consisting essentially of Vitamin A (Palmitate), Vitamin E, Vitamin C, Vitamin D10-02-2008
20080241118Methods and Compositions for Targeting Proteins Across the Blood Brain Barrier - Disclosed are methods and compositions for targeting therapeutic proteins to the brain. Methods and compositions of the invention involve associating an IGF moiety with a therapeutic protein in order to target the therapeutic protein to the brain. Soluble fusion proteins that include an IGF targeting moiety are transported to neural tissue in the brain from blood. Methods and compositions of the invention include therapeutic applications for treating lysosomal storage diseases. The invention also provides nucleic acids and cells for expressing IGF fusion proteins.10-02-2008
20080241117Oral Care Compositions Containing a Mixed Tocopherol Component - An oral care composition, such as a dentifrice composition, which provides enhanced anti-gingivitis efficacy is disclosed. The composition includes a tocopherol component which consists of about 10% to about 90% of gamrnma tocopherol, with the balance of the components selected from alpha tocopherol, beta tocopherol, delta tocopherol, and mixtures thereof.10-02-2008
20080241116Hybrid Recombinases for Genome Manipulation - The present invention provides methods to site-specifically manipulate genomes by using hybrid recombinases. Hybrid recombinases comprise a modified catalytic domain from a unidirectional serine phage integrase, fused to a foreign DNA recognition domain.10-02-2008
20110274679Compositions and Methods of SIRT Activation - Compositions and methods of SIRT activation are presented in which one or more vitamin compounds, and especially vitamin B compounds are used to significantly increase SIRT activity in vitro and in vivo. In especially preferred compositions, vitamin B6, vitamin B12, and vitamin B2 are present in synergistic quantities.11-10-2011
20110274678Beverage - A nutritional beverage composition for providing nutrition to a patient suffering from a kidney ailment comprises a flavor component and a natural sweetener, and is further characterized in that it does not contain amounts of particular ingredients that may not be desirable in treating kidney ailments. In one embodiment of the present invention, the beverage composition lacks substantially any potassium, phosphorous, magnesium, high fructose corn syrup, vitamin A, vitamin K, or vitamin E.11-10-2011
20110274677Biological Pest Control Mixture Containing D-Limonene and Nutmeg Oil - An organic pest control product comprising nutmeg oil and D-limonene is disclosed. In some embodiments the organic pest control product further comprises a miscibility enhancer to enhance the effectiveness of the product. In some embodiments the miscibility enhancer can comprise a liquid soap or detergent. Additional formulations that comprise cassia oil and/or eucalyptus oil are also disclosed. A method of use of an organic pest control product is also disclosed, in which the organic pest control product is effective to control a wide range of biological pests including fungi, bacteria, and insects, including those responsible for Dutch Elm Disease, fire blight, and Colony Collapse Disorder.11-10-2011
20110262417COMPOSITION USEFUL FOR THE PREVENTION OR REDUCTION OF THE PROGRESSION OF PROSTATE CANCER - It is described a composition comprising as active ingredients green tea extract and pomegranate extract for the prevention or reduction of the progression of prostate cancer.10-27-2011
20130171120COMPOSITION FOR ENHANCING PHYSICAL PERFORMANCE - This invention relates to a composition that contains quercetin, vitamin B1, vitamin B2, vitamin B3, vitamin B6, vitamin B12, vitamin C, caffeine, epigallocatechin gallate, epicatechin, epicatechin gallate, and epigallocatechin.07-04-2013
20130142768Method for Improving Eye Health - The present invention relates to a method for promoting eye health by administering to a companion animal a composition comprising at least one polyphenol selected from the group consisting of rosemary, rosemary extract, coffeic acid, coffee extract, turmeric extract, cucurmin, blueberry extract, grapeseed extract, rosemarinic acid, tea extract, and mixtures thereof.06-06-2013
20130142767COMPOSITION CONTAINING REDUCED COENZYME Q10, AND MANUFACTURING AND STABILISING METHODS THEREFOR - The present invention relates to a method of producing reduced coenzyme Q10, including reducing oxidized coenzyme Q10 using a reducing agent in terpenes that can highly dissolve oxidized coenzyme Q10 and reduced coenzyme Q10 in the co-existence of at least one kind of additive selected from the group consisting of alcohols, water, a surfactant and diacylglycerol. In addition, the present invention relates to a composition comprising terpenes, a reducing agent, reduced coenzyme Q10 and at least one kind selected from the group consisting of alcohols, water, a surfactant and diacylglycerol, and a method of stabilizing reduced coenzyme Q10 comprising preparing the composition.06-06-2013
20130177543Natural Means of Augmenting Endogenous Stem Cell Numbers - Disclosed are compositions of matter, uses, and therapeutic interventions directed towards modulation of stem cell activity in a mammal. In particular the invention provides compositions whose end result modulates health, wellbeing, longevity and function of organ systems. Within the scope of the invention are biologically active extracts, components thereof, and compositions (such as cosmetic or pharmaceutical preparations) made comprising such.07-11-2013
20130177544BIOMARKERS ASSOCIATED WITH PRE-DIABETES, DIABETES AND DIABETES RELATED CONDITIONS - Biomarkers for pre-Diabetes, Diabetes and/or a Diabetes related conditions, and methods of their use, including the biomarkers in Tables 1 and 2 such as peroxiredoxin-2, complement C1q subcomponent subunit B, sulfhydryl oxidase 1 and apolipoprotein A-IV.07-11-2013
20090186009SOLID MATTER CONTAINING COENZYME Q - The present invention provides a coenzyme Q-containing solid wherein coenzyme Q fine particles are dispersed in particles made of a physically crosslinked polymer. In addition, the present invention provides a method of producing a coenzyme Q-containing solid, which includes a step of bringing an atomized water-soluble polymer solution capable of forming a physical gel, wherein coenzyme Q is dispersed, into contact with an atomized gelling solution.07-23-2009
20130202572CAFFEINE-FREE DIETARY SUPPLEMENTS FOR INCREASING ENERGY AND METHODS OF ADMINISTERING THE SAME - Disclosed herein are caffeine-free dietary supplements for increasing energy in a subject and methods of administering the same. The method comprises administering to a subject a caffeine-free dietary supplement comprising omega-3 fatty acids, resveratrol, beta-alanine, gamma aminobutyric acid, and valerian root extract product, in amounts such that the supplement is effective for increasing energy and mental focus and relieving stress in the subject.08-08-2013
20080219963Composition Containing Micronutrients With Improved Anti-Oxidant Activity And The Use Thereof - Compositions in fine powder form that can be obtained by means of a dry co-grinding process of an at least ternary mixture consisting of an active substance, a carrier and at least one auxiliary co-grinding substance, wherein the active substance is constituted by one or more micronutrient substances with particular antioxidant activity. Such compositions have shown a significant increase in active substance antioxidant power in comparison to solutions of equal active substance content. Said effect is particularly useful for uses for active substances included in antioxidant compositions in the pharmaceutical, cosmetic and dietary-nutritional fields.09-11-2008
20120251515Endopeptidase Treatment of Cosmesis Disorders - The present specification discloses TEMs, compositions comprising such TEMs, compositions comprising such TEMs and Clostridial toxins, methods of treating a cosmesis disorder in an individual using such compositions, use of such TEMs in manufacturing a medicament for treating a cosmesis disorder, use of such TEMs and Clostridial toxins in manufacturing a medicament for treating a cosmesis disorder, use of such TEMs in treating a cosmesis disorder, and use of such TEMs and Clostridial toxins in treating a cosmesis disorder.10-04-2012
20110268718CACTUS FRUIT EXTRACT - A method for producing a cactus fruit extract for use in formulating a beverage which can be used in the treatment of veisalgia.11-03-2011
20110268717Herbal-Based Compositions for Alleviating Symptoms Associated with Autism - Aspects of the invention relate to compositions comprising passiflora extracts that may improve neurological and behavioral symptoms associated with Pervasive Developmental Disorders.11-03-2011
20130136724PIG FEED, AND METHOD FOR FEEDING SAME - An object of the present invention is to provide a method for improving a farrowing rate of sows or improving growth and productivity of postnatal piglets, and a feed used in the method. The present invention relates to a method for improving a farrowing rate of a sow or improving growth and productivity of postnatal piglets, the method comprising administering coenzyme Q to a swine.05-30-2013
20130136725COMPOSITIONS FOR SYSTEMIC TREATMENT OF PATHOLOGICAL CONDITIONS RESULTING FROM OXIDATIVE STRESS AND/OR REDOX IMBALANCE - Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or thionate compounds and/or any chemical species capable of providing to a subject in need thereof a sulfide compound, thiosulfate compound, thionite compound, or thionate compound. The unique compositions of this invention contain one or more “active sulfur substances” in combination with each other or with other therapeutic agents. The invention also encompasses the varying modes of administration of the therapeutic substances. In particular, a novel method of combining active ingredient with wet cellulose is provided, which allows the wet cellulose to function as an enteric carrier.05-30-2013
20130177542Osteoporosis Treatment Means and Method - Supplements (non-hormonal) known to aid in bone formation and a method of spreading the supplements out throughout the day taking into consideration counteracting effects some have on others and according to when the body is more likely to need them while keeping in mind consumer compliance, which consensus suggests 3 times per day would be a maximum. (including in some instances an additional bed-time capsule).07-11-2013
20130115202ANTI-INFLAMMATORY COMPOSITIONS FOR TREATING NEURO-INFLAMMATION - This disclosure pertains to methods of treating a neuro-inflammation disorder in a subject, comprising administering to a subject in need thereof an effective amount of a composition comprising a flavonoid, or a structurally related analogue, olive kernel extract, hydroxytyrosol, and berberine, and, optionally, one or more ingredients selected from the group consisting of a sulfated proteoglycan, oleocanthal, a CRH antagonist, S adenosylmethionine, a histamine 1 receptor antagonist, a histamine 3 receptor agonist, emu oil, oregano oil, grape seed oil, aloe extract, biotin, and selenium. Certain of the present compositions are useful in protecting against or treating neuro-inflammation associated with allergies, Alzheimer's disease (AD), atherosclerosis, asthma, Autistic Spectrum Disorders (ASD).05-09-2013
20130115201Fluid Supplement with Prenatal Vitamins - A fluid supplement is provided that is specifically tailored to meet the health and nutritional needs of a pregnant woman and her developing fetus. The fluid supplement also combats the symptoms of nausea and vomiting that are commonly associated with pregnancy. The fluid supplement contains vitamins, minerals, dietary supplements, and flavor-enhancing ingredients in amounts that safely provide health and nutritional benefits to both the woman and her developing fetus. By using the fluid supplement, a pregnant woman is able to obtain the health and nutritional benefits in a single dose of a palatable fluid supplement instead of having to swallow multiple pills per day.05-09-2013
20130121980METHOD FOR SEPARATING COMPONENTS IN NATURAL OIL - Different components of natural oils are separated by forming solid complexes of components of the natural oil with a solvent, and then separating the solid complexes from the remaining liquids. The natural oil is cooled in the presence of a solvent, and at least one component of the oil forms the solid complex with the solvent. This solid complex is separated from the remaining liquid portion of the oil solution, which also contains the solvent. Additional options concentration steps can further concentrate the components left in the liquid phase.05-16-2013
20130095089GLUCOSYLCERAMIDE SYNTHASE INHIBITORS AND THERAPEUTIC METHODS USING THE SAME - Glucosylceramide synthase inhibitors and compositions containing the same are disclosed. Methods of using the glucosylceramide synthase inhibitors in the treatment of diseases and conditions wherein inhibition of glucosylceramide synthase provides a benefit, like Gaucher disease and Fabry disease, also are disclosed.04-18-2013
20130095088Topical skin care formulations - A topical anti-aging skin care formulation comprising an effective amount of a benzoquinone, such as CoQ10, plus a synergistic pair of stabilizers and a synergistic pair of whiteners. The stabilizers are octyl salicylate and octyl methoxycinnamate. The whiteners are titanium dioxide and zinc oxide. When proper amounts of these ingredients are used in an aqueous based emulsion formulation, the product will be initially white, and will remain white for an extended period of time.04-18-2013
20130101569HAIR GROWTH STIMULANT - A composition of a mixture of vitamin and herbal supplements. Supplementation of the composition promotes hair growth and thickness by increasing the number of hairs and preventing hair loss. The concentration of the vitamin and herbal supplements in the composition is suitably about 0.01-100%. The composition may comprise a suitable carrier, solvent and/or emulgent. The composition may be, for example, an internally ingested tablet, a capsule, drops or a suspension. This formulation will enhance the hair thickness and provide elements for growing hair in humans and animals.04-25-2013
20130142769TREATMENT OF COGNITIVE DISORDERS - The invention relates to treatments of cognitive disorders e.g. Mild Cognitive Disorder comprising the use of agents which are capable of lowering homocysteine levels in a subject, preferably a human subject. Aspects of the invention relate to a method of treating such disorders comprising administering one or more B vitamins e.g. folic acid, Vitamin B06-06-2013
20100278799Composition for Improving Nutritional Status, Reducing Frequency of Fever and/or Increasing Immunocompetence of the Elderly - Provided is a composition for improving the nutritional status, reducing the frequency of fever, and/or increasing the immunocompetence of the elderly. The composition is one for improving the nutritional status, reducing the frequency of fever, and/or increasing the immunocompetence of the elderly and comprises the following components (a) to (e): (a) an antioxidant agent; (b) at least one component selected from the group consisting of vitamin B11-04-2010
20100278798METHODS AND SYSTEMS FOR FORMING BIOCOMPATIBLE MATERIALS - Methods and systems forming biocompatible materials are disclosed herein. Forming a biocompatible material may include contacting a liquid, having a linking material, with an adjoining material having embedded therein a nucleating material that causes the linking material to nucleate and grow into the liquid. After a time sufficient to cause the linking material to grow substantially from the nucleating material into a space occupied by the liquid, the liquid may be solidified to form a solid such that the linking material secures the solid to the adjoining material.11-04-2010
20110217278Medication and Treatment for Disease - A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 μg vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.09-08-2011
20080199447CATALYTIC DOMAIN OF ADAM33 AND METHODS OF USE THEREOF - The present invention discloses purified polypeptides that comprise an active ADAM33 catalytic domain. In addition, the present invention discloses nucleic acids that encode the polypeptides of the present invention. The present invention also discloses methods of growing X-ray diffractable crystals of polypeptides comprising the active ADAM33 catalytic domain. In addition, the present invention discloses methods of using the X-ray diffractable crystals of ADAM33 in structure-based drug design to identify compounds that can modulate the enzymatic activity of ADAM33. The present invention also discloses methods of treating respiratory disorders by administering therapeutic amounts of the ADAM33 catalytic domain.08-21-2008
20110243907COSMETIC AND NUTRITIONAL ALPHA-OMEGA COMPLEX COMPOSITION - The present invention is an alpha omega complex composition for use in cosmetic and nutritional products and formulations for a user that contains coenzyme Q10, selenium sulfide and n-acetyl cysteine. Specific cosmetic and nutritional products and formulations include face cream, night cream, eye cream, lip cream, shampoos, conditioners, hand cream, body cream, daily dietary supplements, hair regeneration cream, anti-acne cream, anti-radiation cream, skin serum, eye-lash regeneration lotion and exfoliate products and formulations. One embodiment of the alpha omega complex composition would include 2.5% by volume NAC, 0.1% by volume Q10 and 0.05% by volume SeS10-06-2011
20100284984ADENOSINE AND ITS MIMETICS. MODULATORS, TRANSPORT INHIBITORS, AND RECEPTOR AGONISTS AS A THERAPEUTIC TOOL TO REPLACE OR IMPROVE THE EFFICACY OF DEEP BRAIN STIMULATION - The present invention relates to a method of enhancing brain stimulation of a subject. This method involves selecting a subject in need of brain stimulation and electrically stimulating the brain of the subject. Adenosine, an adenosine mimetic, an adenosine modulator, an adenosine transport inhibitor, or an adenosine receptor agonist are administered to the subject under conditions effective to enhance electrical stimulation of the brain of the subject. The administration of adenosine, an adenosine mimetic, an adenosine modulator, an adenosine transport inhibitor, or an adenosine receptor agonist to the subject can alternatively be carried out with electrically stimulating the brain of the subject.11-11-2010
20100291057Composition for Reducing Oxidative Stress and/or Side Effects Occurring During Cancer Chemotherapy or Improving Nutritional Status During Cancer Chemotherapy - Provided is a composition for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving a nutritional status during cancer chemotherapy. The composition is one for reducing oxidative stress and/or side effects occurring during cancer chemotherapy or improving nutritional status during cancer chemotherapy and comprises the following components (a) to (f): (a) an antioxidant agent; (b) at least one component selected from the group consisting of vitamin B11-18-2010
20100303784PREPARATION FOR THE PREVENTION AND/OR TREATMENT OF VASCULAR DISORDERS - The present invention relates to a preparation suitable for the prevention and/or treatment of vascular disorders, comprising the following fractions: 12-02-2010
20130156745COMPOSITION FOR ENZYMATIC DEBRIDEMENT - Methods and compositions for the enzymatic debridement of wounds are provided. Methods for preparing enzymatic debridement compositions are also provided. In one embodiment, an enzymatic debridement composition prepared by dissolving crude bromelain in a composition comprising a weak acid, and filtering and/or dialyzing the dissolved crude bromelain to obtain the enzymatic debridement composition is provided.06-20-2013
20130156746COMPOSITION AND METHOD OF MANUFACTURE - A dietary supplement composition includes a synergistic combination of saffron and resveratrol for providing anti-oxidant and gene modulation effects for preventing, ameliorating and/or reducing a rate of development and progression of age-related macular degeneration (AMD). Optionally, the combination is supplemented with one or more further ingredients: fish oil, Zinc, Copper, vitamin C, vitamin E, lutein, zeaxanthin. The combination is beneficially provided as a composition which is useful for reducing a risk of developing, and/or for reducing a rate of progression of age-related macular degeneration, and/or for preventing age-related sight loss, and other age-related diseases.06-20-2013
20130183277NUTRIENT COMPOSITIONS AND METHODS FOR ENHANCED EFFECTIVENESS OF THE IMMUNE SYSTEM - Provided are compositions and methods for increasing patient CD4+ cell count while undergoing treatment for immune-mediated disease, cancer, heart disease, neurodegenerative disease, or infectious disease by administering to the patient a nutrient composition including, inter alia, alpha lipoic acid, acetyl L-carnitine, and N-acetyl-cysteine.07-18-2013
20130183278METHOD FOR DIAGNOSIS - The present invention relates to method of identifying whether or not an individual has Parkinson's disease (PD). In particular, the invention relates to a method for identifying whether or not an individual has PD as opposed to another neurodegenerative disease. The method of the invention comprises measuring the concentration of α-synuclein (α-syn) and the concentration of unphosphorylated tau (tau) and/or phosphorylated tau (p-tau) in a cerebrospinal fluid sample taken from an individual. The method also comprises calculating the ratio of the concentration of tau and/or p-tau to the concentration of α-syn, and thereby determining whether or not the individual has PD.07-18-2013
20110311504COENZYME Q10-CONTAINING COMPOSITION FOR ORAL INGESTION - Disclosed are: a coenzyme Q10 composition for oral ingestion which improves the bioabsorbability of coenzyme Q10 and enables efficient ingestion of coenzyme Q10 and which is highly safe, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion. Combining coenzyme Q10 and a seed processed product has made it possible to provide a coenzyme Q10-containing composition for oral ingestion excellent in bioabsorbability, and a pharmaceutical preparation and a functional food containing the composition for oral ingestion.12-22-2011
20130189237CO-ENZYME Q10 FORMULATIONS AND METHODS OF USE - Topical formulations of CoQ10 reduce the rate of tumor growth in an animal subject. In the experiments described herein, CoQ10 was shown to increase the rate of apoptosis in a culture of skin cancer cells but not normal cells. Moreover, treatment of tumor-bearing animals with a topical formulation of CoQ10 was shown to dramatically reduce the rate of tumor growth in the animals.07-25-2013
20120009170METHOD OF TREATING INFLAMMATORY LUNG DISEASE WITH SUPPRESSORS OF CpG OLIGONUCLEOTIDES - The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for inhibiting or treating inflammatory lung disease by administering a therapeutically effective amount of a suppressive oligodeoxynucleotide.01-12-2012
20120020945Food Supplement and Method for Enhancing Athletic Performance - Food supplements comprising 01-26-2012
20130195827NUTRIGENOMIC METHODS TO OVERCOME CARBOHYDRATE BINGEING AND OVEREATING - This invention concerns Reward Deficiency Syndrome (RDS) and obesity, and the role of catecholaminergic pathways in aberrant substance-seeking behavior, in particular cravings for carbohydrates. Also described are new nutrigenomic formulas having unique combinations of ingredients having a generalized anti-craving effect are, which can inhibit carbohydrate bingeing, inducing significant healthy fat loss and relapse prevention, as well genetic testing for certain polymorphisms correlated with RDS behaviors.08-01-2013
20120082653METHODS OF LYSOSOMAL STORAGE DISEASE THERAPY - Methods of treating a lysosomal storage disorder and methods of increasing cellular uptake of a lysosomal enzyme using β2 agonists or therapeutic agents that increase expression of receptors for a lysosomal enzyme.04-05-2012

Patent applications in class ENZYME OR COENZYME CONTAINING

Patent applications in all subclasses ENZYME OR COENZYME CONTAINING